<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992536</url>
  </required_header>
  <id_info>
    <org_study_id>V102_03E1</org_study_id>
    <secondary_id>2012-003937-41</secondary_id>
    <nct_id>NCT01992536</nct_id>
  </id_info>
  <brief_title>Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)</brief_title>
  <official_title>Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this extension study is to evaluate the immunogenicity and safety of a booster
      dose of a MenABCWY vaccine, administered 24 months after completion of the primary
      vaccination series, in subjects who previously received the same vaccine formulation in study
      V102_03 (NCT01272180) (Groups I and II). Antibody persistence at 24 and 36 months after the
      primary vaccination and 12 months after the booster dose will also be evaluated in these
      subjects.

      In addition, safety and immunogenicity of two investigational MenABCWY vaccine formulations
      (either a MenABCWY+ OMV or a MenABCWY+¼ OMV) will be assessed in subjects who previously
      received two doses of MenB vaccine (Group III) or one dose of Menveo vaccine (Group IV).
      These subjects will be followed for safety and immunogenicity for 12 months after vaccination
      in study V102_03E1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Percentages of Subjects With HT-hSBA (High-throughput Human Serum Bactericidal Assay) Seroresponse Against N. Meningitidis Serogroups A, C, W and Y.</measure>
    <time_frame>Day 30</time_frame>
    <description>Percentages of subjects having HT-hSBA seroresponse against N. meningitidis serogroups A, C, W and Y, following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180). Seroresponse to N. meningitidis serogroups A, C, W and Y is defined as: for subjects with a pre-vaccination HT-hSBA titer &lt; 1:4, a post-vaccination hSBA titer ≥ 1:8; for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Percentage of Subjects With HT-hSBA Titers ≥ 1:5 Against Strains of N. Meningitidis Serogroups B.</measure>
    <time_frame>Day 1 and Day 30</time_frame>
    <description>Percentage of subjects reporting HT-hSBA titers ≥ 1:5 against strains of N. meningitidis serogroups B at baseline (Day 1) and one month (Day 30) following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitides Serogroups A, C, W, Y.</measure>
    <time_frame>Day 1 (Pre vaccination)</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 in serogroups A, C, W, Y against N. meningitides assessed prior to the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.</measure>
    <time_frame>Day 1 (Pre vaccination)</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitidis strains of serogroup B assessed prior to the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. The HT-hSBA Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroups A, C, W,Y.</measure>
    <time_frame>Day 1 (Pre-vaccination)</time_frame>
    <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y prior the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroup B.</measure>
    <time_frame>Day 1 (Pre-vaccination)</time_frame>
    <description>The HT-hSBA GMTs against N. meningitidis strains of serogroup B prior the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.</measure>
    <time_frame>Day 1 and Day 30</time_frame>
    <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y at Day 1 and Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.</measure>
    <time_frame>Day 1 and Day 30</time_frame>
    <description>The HT-hSBA GMTs against N. meningitidis strains of serogroups B at Day 1 and Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.</measure>
    <time_frame>Day 1 and Day 30</time_frame>
    <description>Percentage of subjects with four-fold rise in HT-hSBA titers against N. meningitidis serogroup B strains, from Day 1 (baseline) to Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.
Four-fold rise is defined as follows: for subjects with a pre-vaccination titer &lt; 1:2, a post-titer of ≥ 1:8; for subjects with a pre-vaccination titer ≥ 1:2 at least a four-fold increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 Against N. Meningitidis Serogroups A,C,W,Y.</measure>
    <time_frame>Day 1 and Day 30</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 to N. meningitidis serogroups A,C,W,Y at Day 1 and Day 30 (one month) after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 Against N. Meningitidis Serogroup B Strains.</measure>
    <time_frame>Day 1 and Day 30</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 to N. meningitidis serogroup B strains at Day 1 and Day 30 (one month) after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12. Percentage of Subjects With Seroresponse to N. Meningitidis Serogroups A, C, W and Y, at Day 30 After Booster Vaccination in This Study.</measure>
    <time_frame>Day 30</time_frame>
    <description>Percentage of subjects with seroresponse to N. meningitidis serogroup A, C, W and Y, at Day 30 after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.</measure>
    <time_frame>Day 1 and Day 365</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 against N. meningitidis serogroups A, C, W, Y, at 24 and 36 months after the primary vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B</measure>
    <time_frame>Day 1, Day 30 and Day 365</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitidis strains of serogroup B, at 24 and 36 months after the primary vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>15. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.</measure>
    <time_frame>Day 1, Day 30 and Day 365</time_frame>
    <description>Percentage of subjects with four-fold rise in HT-hSBA titers against N. meningitidis serogroup B strains, at 24 and 36 months after the primary vaccination.
Four-fold rise is defined as follows: for subjects with a pre-vaccination titer &lt; 1:2, a post-titer of ≥ 1:8; for subjects with a pre-vaccination titer ≥ 1:2 at least a four-fold increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>16. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.</measure>
    <time_frame>Day 1 and Day 365</time_frame>
    <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y, at 24 and 36 months after the primary vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>17. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.</measure>
    <time_frame>Day 1 and Day 365</time_frame>
    <description>The HT-hSBA GMTs against N. meningitidis strains of serogroups B, at 24 and 36 months after the primary vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.</measure>
    <time_frame>Day 1, Day 30 and Day 365</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 against N. meningitidis serogroups A, C, W, Y at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>19. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.</measure>
    <time_frame>Day 1, Day 30 and Day 365</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitides strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>20. The HT-hSBA GMTs Against Neisseria Meningitidis Serogroups A, C, W,Y and Strains of Serogroups B.</measure>
    <time_frame>Day 1, Day 30 and Day 365</time_frame>
    <description>The HT-hSBA GMTs against Neisseria meningitidis serogroup A, C, W, Y and strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>21. The HT-hSBA GMTs Against Neisseria Meningitidis Strains of Serogroups B.</measure>
    <time_frame>Day 1, Day 30 and Day 365</time_frame>
    <description>The HT-hSBA GMTs against Neisseria meningitidis strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>22. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A,C,W,Y at 12 Months After Booster Vaccination.</measure>
    <time_frame>Day 1, Day 30 and Day 365</time_frame>
    <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 to N. meningitidis serogroups A,C,W,Y at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>23. Number of Subjects With Solicited Local and Systemic Adverse Events Following Booster Vaccination in This Study.</measure>
    <time_frame>From day 1 (6 hours) through day 7 after any vaccination</time_frame>
    <description>Number of subjects reporting solicited local and systemic adverse events after receiving a booster dose of MenABCWY vaccine or placebo. the below reported events are Erythema- Injection site erythema, Induration- Injection site induration, Pain-injection site pain, Arthralgia, Chills, Fatigue, Headache, Loss of Appetite, Myalgia, Nausea, Rash, Fever, Prevention- Prevention of Pain and/or Fever, Treatment- Treatment of Pain and/or Fever and Analgesic/Antipyr.: use of Analgesic/Antipyretics in pain and fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24. Number of Subjects With Unsolicited (Any AEs and Possibly Related AEs) Following Booster Vaccination in This Study.</measure>
    <time_frame>Day 1 through Day 30</time_frame>
    <description>Number of subjects reporting unsolicited AEs (any AEs and at least possibly related AEs) after receiving a booster dose of MenABCWY vaccine or placebo from Day 1 to Day 30.
Analysis was done on the Unsolicited Safety Set. All subjects in the exposed population who provided information about post-vaccination AEs or safety records at Day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25. Number of Subjects With Unsolicited Adverse Events Following Booster Vaccination in This Study.</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>Number of subjects reporting any serious unsolicited AEs (SAEs), possibly related SAEs, medically attended AEs, unsolicited AEs leading to withdrawal and deaths after receiving a booster dose of MenABCWY vaccine or placebo, are reported for the entire study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>26. Number of Subjects With Unsolicited Adverse Leading to New Onset Chronic Disease (NOCD) Before Study Vaccination.</measure>
    <time_frame>From primary parent study completion up to Day 1 in this study.</time_frame>
    <description>Number of subjects reporting New Onset Chronic Disease (NOCD),from the end of the primary parental study V102_03 (NCT01272180) up to Day 1 visit in V102_03E1 study, is reported. (Any NOCD AEs: NOCD V102_03 (NCT01272180) vs. NOCD- Day 1, V102_03E1)</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Ia: MenABCWY+OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ib: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIa: MenABCWY+¼OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIb: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIIa: MenABCWY+OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIIb: MenABCWY+¼OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVa: MenABCWY+OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVb: MenABCWY+¼OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVc: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenABCWY+OMV</intervention_name>
    <description>Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a &quot;full&quot; dose) plus the fully lyophilized MenACWY vaccine</description>
    <arm_group_label>Ia: MenABCWY+OMV</arm_group_label>
    <arm_group_label>IIIa: MenABCWY+OMV</arm_group_label>
    <arm_group_label>IVa: MenABCWY+OMV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenABCWY+¼OMV</intervention_name>
    <description>Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine</description>
    <arm_group_label>IIa: MenABCWY+¼OMV</arm_group_label>
    <arm_group_label>IIIb: MenABCWY+¼OMV</arm_group_label>
    <arm_group_label>IVb: MenABCWY+¼OMV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution for injection (0.5mL)</description>
    <arm_group_label>Ib: Placebo</arm_group_label>
    <arm_group_label>IIb: Placebo</arm_group_label>
    <arm_group_label>IVc: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females that received both vaccinations and completed the Study Termination
             visit in the primary study, V102_03 (NCT01272180);

          2. Individuals or the individual's parents or legal guardian who have given written
             consent after the nature of the study has been explained according to local regulatory
             requirements;

          3. Individuals who have given written assent as required by local regulations after the
             nature of the study has been explained to them according to local regulatory
             requirements;

          4. Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator;

          5. Individuals and/or or the individual's parents or legal guardian who can comply with
             study procedures and are available for follow-up.

        Exclusion Criteria:

          1. History of any meningococcal vaccine administration other than the vaccination
             administered in the primary study, V102_03 (NCT01272180);

          2. Current or previous, confirmed or suspected disease caused by N. meningitidis;

          3. Household contact with and/or intimate exposure to an individual with any laboratory
             confirmed N. meningitidis infection within 60 days of enrollment;

          4. History of severe allergic reactions after previous vaccinations or hypersensitivity
             to any vaccine component;

          5. All sexually active females that have not used an &quot;acceptable contraceptive method(s)&quot;
             for at least 2 months prior to study entry. Acceptable birth control methods are
             defined as one or more of the following:

               1. Hormonal contraceptive (such as oral, injection, transdermal patch, implant,
                  cervical ring)

               2. Barrier (condom with spermicide or diaphragm with spermicide) each and every time
                  during intercourse

               3. Intrauterine device (IUD)

               4. Monogamous relationship with vasectomized partner. Partner must have been
                  vasectomized for at least six months prior to the subject's study entry;

          6. Sexually active females that refuse to use to an &quot;acceptable contraceptive method&quot;
             through to 3 weeks following the study vaccination;

          7. Female subjects with a positive pregnancy test prior to the study vaccine being
             administered;

          8. Nursing (breastfeeding) mothers;

          9. Individuals with a history of illness or with an ongoing illness that, in the opinion
             of the investigator, may pose additional risk to the subject if he/she participates in
             the study;

         10. Any serious, chronic, or progressive disease (e.g., neoplasm, diabetes, cardiac
             disease, hepatic disease, progressive neurological disease or seizure disorder;
             autoimmune disease, HIV infection or AIDS, blood dyscrasias, bleeding diathesis, signs
             of cardiac or renal failure, or severe malnutrition);

         11. Subjects who required chronic administration (defined as more than 14 days) of
             immunosuppressants or other immune-modifying drugs within six months prior to the
             study vaccination. (For corticosteroids, this means prednisone, or equivalent, ≥
             20mg/day. Inhaled and topical steroids are allowed).

         12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral
             immunoglobulin preparation within the previous 90 days;

         13. Individuals participating in any clinical trial with another investigational product
             30 days prior to first study visit or intent to participate in another clinical study
             at any time during the conduct of this study;

         14. Administration or planned administration, of any vaccine not foreseen by the study
             protocol within 30 days prior study vaccination, and up to 30 days after the
             vaccination (with the exception of any licensed influenza vaccine which may be
             administered &gt;14 days preceding or &gt;14 days following the study vaccination);

         15. Individuals who study personnel or immediate family members of study personnel
             including brother, sister, child, parent, or the spouse.

         16. Individuals who have experienced moderate or severe acute infection and/or fever
             (defined as temperature ≥ 38°C) within 3 days prior to enrolment.

         17. Who have received systemic antibiotic treatment within 7 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 23, Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24, Madera Family Medical Group 1111 West 4th Street</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25, Center for Clinical Trials LLC 16660 Paramount Blvd, Suite 301</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28, Kentucky Pediatric/Adult Research 201 South 5th Street</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21, Bluegrass Clinical Research Inc. 5512 Bardstown Road, Suite 2</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26, Ohio Pediatric Research Association 7200 Poe Ave, Suite 200</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27, Ohio Pediatric Research Association 1775 Delco Park Drive</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22, Focus Research Group 201 Signature Place</name>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15, Specjalistyczna Przychodnia Lekarska Internistyczno-Pediatryczna, Juniperus&quot; s.c.</name>
      <address>
        <city>ul.Kościuszki 41</city>
        <state>Izabelin</state>
        <zip>05-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13, Hanna Czajka Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>ul. Braci Kiemliczów 14</city>
        <state>Kraków</state>
        <zip>31-223</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12, NZOZ PRAKTIMED Sp.zo.o</name>
      <address>
        <city>ul.Strzelców 15</city>
        <state>Kraków</state>
        <zip>31-422</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14, Klinika Pediatrii Centrum Medycznego Kształcenia Podyplomowego,Szpital Bielański</name>
      <address>
        <city>ul. Cegłowska 80</city>
        <state>Warszawa</state>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11, Katedra i Klinika Pediatrii i Chorób Infekcyjnych</name>
      <address>
        <city>ul.O.Bujwida 44</city>
        <state>Wrocław</state>
        <zip>50-354</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>April 14, 2016</results_first_submitted>
  <results_first_submitted_qc>August 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2016</results_first_posted>
  <disposition_first_submitted>April 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 7, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 25, 2015</disposition_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal</keyword>
  <keyword>Booster</keyword>
  <keyword>MenABCWY</keyword>
  <keyword>Menveo</keyword>
  <keyword>Vaccine Adolescents</keyword>
  <keyword>Immune Response</keyword>
  <keyword>N. Meningitidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 5 study sites in Poland and from 8 study sites in United States.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2OMV_OMV</title>
          <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
        </group>
        <group group_id="P2">
          <title>2OMV_Pbo</title>
          <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="P3">
          <title>2qOMV_qOMV</title>
          <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
        </group>
        <group group_id="P4">
          <title>2qOMV_Pbo</title>
          <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="P5">
          <title>2B_OMV</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
        </group>
        <group group_id="P6">
          <title>2B_qOMV</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
        </group>
        <group group_id="P7">
          <title>2B_Pbo</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of Placebo in this study.</description>
        </group>
        <group group_id="P8">
          <title>1M_OMV</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
        </group>
        <group group_id="P9">
          <title>1M_qOMV</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
        </group>
        <group group_id="P10">
          <title>1M_Pbo</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="18"/>
                <participants group_id="P10" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2OMV_OMV</title>
          <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
        </group>
        <group group_id="B2">
          <title>2OMV_Pbo</title>
          <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="B3">
          <title>2qOMV_qOMV</title>
          <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
        </group>
        <group group_id="B4">
          <title>2qOMV_Pbo</title>
          <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="B5">
          <title>2B_OMV</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
        </group>
        <group group_id="B6">
          <title>2B_qOMV</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
        </group>
        <group group_id="B7">
          <title>2B_Pbo</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of Placebo in this study.</description>
        </group>
        <group group_id="B8">
          <title>1M_OMV</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
        </group>
        <group group_id="B9">
          <title>1M_qOMV</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
        </group>
        <group group_id="B10">
          <title>1M_Pbo</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="21"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="21"/>
            <count group_id="B9" value="19"/>
            <count group_id="B10" value="19"/>
            <count group_id="B11" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" spread="5.19"/>
                    <measurement group_id="B2" value="17.1" spread="4.31"/>
                    <measurement group_id="B3" value="18" spread="5.05"/>
                    <measurement group_id="B4" value="19" spread="5.4"/>
                    <measurement group_id="B5" value="20.9" spread="3.99"/>
                    <measurement group_id="B6" value="19.7" spread="5.36"/>
                    <measurement group_id="B7" value="17.9" spread="4.67"/>
                    <measurement group_id="B8" value="16.8" spread="4.65"/>
                    <measurement group_id="B9" value="19.2" spread="6.1"/>
                    <measurement group_id="B10" value="17.6" spread="5.19"/>
                    <measurement group_id="B11" value="18.4" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1. Percentages of Subjects With HT-hSBA (High-throughput Human Serum Bactericidal Assay) Seroresponse Against N. Meningitidis Serogroups A, C, W and Y.</title>
        <description>Percentages of subjects having HT-hSBA seroresponse against N. meningitidis serogroups A, C, W and Y, following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180). Seroresponse to N. meningitidis serogroups A, C, W and Y is defined as: for subjects with a pre-vaccination HT-hSBA titer &lt; 1:4, a post-vaccination hSBA titer ≥ 1:8; for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.</description>
        <time_frame>Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>1. Percentages of Subjects With HT-hSBA (High-throughput Human Serum Bactericidal Assay) Seroresponse Against N. Meningitidis Serogroups A, C, W and Y.</title>
          <description>Percentages of subjects having HT-hSBA seroresponse against N. meningitidis serogroups A, C, W and Y, following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180). Seroresponse to N. meningitidis serogroups A, C, W and Y is defined as: for subjects with a pre-vaccination HT-hSBA titer &lt; 1:4, a post-vaccination hSBA titer ≥ 1:8; for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.</description>
          <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="94" lower_limit="69.8" upper_limit="99.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (N=20,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O2" value="100" lower_limit="69.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (N=20,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O2" value="85" lower_limit="54.6" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (N=25,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>2. Percentage of Subjects With HT-hSBA Titers ≥ 1:5 Against Strains of N. Meningitidis Serogroups B.</title>
        <description>Percentage of subjects reporting HT-hSBA titers ≥ 1:5 against strains of N. meningitidis serogroups B at baseline (Day 1) and one month (Day 30) following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180).</description>
        <time_frame>Day 1 and Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>2. Percentage of Subjects With HT-hSBA Titers ≥ 1:5 Against Strains of N. Meningitidis Serogroups B.</title>
          <description>Percentage of subjects reporting HT-hSBA titers ≥ 1:5 against strains of N. meningitidis serogroups B at baseline (Day 1) and one month (Day 30) following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180).</description>
          <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N= 25,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="54.9" upper_limit="90.6"/>
                    <measurement group_id="O2" value="87" lower_limit="59.5" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N=25,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N=25,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="4.5" upper_limit="36.1"/>
                    <measurement group_id="O2" value="13" lower_limit="1.6" upper_limit="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, N=25,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="79.6" upper_limit="99.90"/>
                    <measurement group_id="O2" value="100" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N=24,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="9.8" upper_limit="46.7"/>
                    <measurement group_id="O2" value="20" lower_limit="4.3" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 30, N=25,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1,N=25,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="18.0" upper_limit="57.5"/>
                    <measurement group_id="O2" value="27" lower_limit="7.8" upper_limit="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30, N=25,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88" lower_limit="63.6" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N=25,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="9.4" upper_limit="45.1"/>
                    <measurement group_id="O2" value="7" lower_limit="0.17" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N=25,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="74.0" upper_limit="99.0"/>
                    <measurement group_id="O2" value="88" lower_limit="63.6" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N=25,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="4.5" upper_limit="36.1"/>
                    <measurement group_id="O2" value="7" lower_limit="0.17" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N=25,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="74.0" upper_limit="99.0"/>
                    <measurement group_id="O2" value="71" lower_limit="44.0" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitides Serogroups A, C, W, Y.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 in serogroups A, C, W, Y against N. meningitides assessed prior to the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
        <time_frame>Day 1 (Pre vaccination)</time_frame>
        <population>Analysis was done on FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects received two doses of MenABCWY + OMV administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects received two doses of MenABCWY + qOMV administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects received two doses of rMenB + OMV, administered two months apart.</description>
          </group>
          <group group_id="O4">
            <title>Menveo</title>
            <description>Subjects received a dose of placebo followed by one dose of MenACWY administered two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>3. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitides Serogroups A, C, W, Y.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 in serogroups A, C, W, Y against N. meningitides assessed prior to the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
          <population>Analysis was done on FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (N=51,40,38,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="15.9" upper_limit="41.7"/>
                    <measurement group_id="O2" value="28" lower_limit="14.6" upper_limit="43.9"/>
                    <measurement group_id="O3" value="29" lower_limit="15.4" upper_limit="45.9"/>
                    <measurement group_id="O4" value="31" lower_limit="19.5" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (N=48,38,38,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="51.6" upper_limit="79.6"/>
                    <measurement group_id="O2" value="68" lower_limit="51.3" upper_limit="82.5"/>
                    <measurement group_id="O3" value="45" lower_limit="28.6" upper_limit="61.7"/>
                    <measurement group_id="O4" value="57" lower_limit="43.2" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (N=50,36,38,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="80.8" upper_limit="97.8"/>
                    <measurement group_id="O2" value="75" lower_limit="57.8" upper_limit="87.9"/>
                    <measurement group_id="O3" value="76" lower_limit="59.8" upper_limit="88.6"/>
                    <measurement group_id="O4" value="68" lower_limit="54" upper_limit="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (N=51,38,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="50.1" upper_limit="77.6"/>
                    <measurement group_id="O2" value="50" lower_limit="33.4" upper_limit="66.6"/>
                    <measurement group_id="O3" value="16" lower_limit="6" upper_limit="31.3"/>
                    <measurement group_id="O4" value="46" lower_limit="32.7" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitidis strains of serogroup B assessed prior to the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
        <time_frame>Day 1 (Pre vaccination)</time_frame>
        <population>Analysis was done on the FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects received two doses of MenABCWY + OMV administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects received two doses of MenABCWY + qOMV administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects received two doses of rMenB + OMV, administered two months apart.</description>
          </group>
          <group group_id="O4">
            <title>Menveo</title>
            <description>Subjects received a dose of placebo followed by one dose of MenACWY administered two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>4. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitidis strains of serogroup B assessed prior to the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
          <population>Analysis was done on the FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (N=51,38,36,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="62.5" upper_limit="87.2"/>
                    <measurement group_id="O2" value="87" lower_limit="71.9" upper_limit="95.6"/>
                    <measurement group_id="O3" value="94" lower_limit="81.3" upper_limit="99.3"/>
                    <measurement group_id="O4" value="19" lower_limit="9.7" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (N=51,39,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="11.3" upper_limit="35.3"/>
                    <measurement group_id="O2" value="18" lower_limit="7.5" upper_limit="33.5"/>
                    <measurement group_id="O3" value="34" lower_limit="19.6" upper_limit="51.4"/>
                    <measurement group_id="O4" value="3" lower_limit="0.41" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (N=50,37,37,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="13.1" upper_limit="38.2"/>
                    <measurement group_id="O2" value="16" lower_limit="6.2" upper_limit="32.0"/>
                    <measurement group_id="O3" value="35" lower_limit="20.2" upper_limit="52.5"/>
                    <measurement group_id="O4" value="7" lower_limit="1.9" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (N=51,38,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="24.1" upper_limit="51.9"/>
                    <measurement group_id="O2" value="29" lower_limit="15.4" upper_limit="45.9"/>
                    <measurement group_id="O3" value="50" lower_limit="33.4" upper_limit="66.6"/>
                    <measurement group_id="O4" value="22" lower_limit="12.3" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (N=51,39,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="17.5" upper_limit="43.8"/>
                    <measurement group_id="O2" value="13" lower_limit="4.3" upper_limit="27.4"/>
                    <measurement group_id="O3" value="26" lower_limit="13.4" upper_limit="43.1"/>
                    <measurement group_id="O4" value="14" lower_limit="6.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=51,39,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="12.8" upper_limit="37.5"/>
                    <measurement group_id="O2" value="8" lower_limit="1.6" upper_limit="20.9"/>
                    <measurement group_id="O3" value="16" lower_limit="6.0" upper_limit="31.3"/>
                    <measurement group_id="O4" value="3" lower_limit="0.41" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5. The HT-hSBA Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroups A, C, W,Y.</title>
        <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y prior the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
        <time_frame>Day 1 (Pre-vaccination)</time_frame>
        <population>Analysis was done on FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects received two doses of MenABCWY + OMV administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects received two doses of MenABCWY + qOMV administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects received two doses of rMenB + OMV, administered two months apart.</description>
          </group>
          <group group_id="O4">
            <title>Menveo</title>
            <description>Subjects received a dose of placebo followed by one dose of MenACWY administered two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>5. The HT-hSBA Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroups A, C, W,Y.</title>
          <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y prior the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
          <population>Analysis was done on FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (N=51,40,38,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" lower_limit="2.19" upper_limit="5.08"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.95" upper_limit="5.60"/>
                    <measurement group_id="O3" value="2.96" lower_limit="1.70" upper_limit="5.17"/>
                    <measurement group_id="O4" value="4.14" lower_limit="2.75" upper_limit="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (N=48,38,38,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="11" upper_limit="30"/>
                    <measurement group_id="O2" value="13" lower_limit="8.00" upper_limit="20"/>
                    <measurement group_id="O3" value="6.05" lower_limit="4.28" upper_limit="8.55"/>
                    <measurement group_id="O4" value="10" lower_limit="6.36" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (N=50,36,38,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="24" upper_limit="52"/>
                    <measurement group_id="O2" value="23" lower_limit="12" upper_limit="45"/>
                    <measurement group_id="O3" value="20" lower_limit="11" upper_limit="34"/>
                    <measurement group_id="O4" value="17" lower_limit="9.65" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (N=51,38,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7.01" upper_limit="23"/>
                    <measurement group_id="O2" value="8.85" lower_limit="4.24" upper_limit="18"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.25" upper_limit="2.60"/>
                    <measurement group_id="O4" value="6.49" lower_limit="3.72" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroup B.</title>
        <description>The HT-hSBA GMTs against N. meningitidis strains of serogroup B prior the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
        <time_frame>Day 1 (Pre-vaccination)</time_frame>
        <population>Analysis was done on the FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects received two doses of MenABCWY + OMV administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects received two doses of MenABCWY + qOMV administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects received two doses of rMenB + OMV, administered two months apart.</description>
          </group>
          <group group_id="O4">
            <title>Menveo</title>
            <description>Subjects received a dose of placebo followed by one dose of MenACWY administered two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>6. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroup B.</title>
          <description>The HT-hSBA GMTs against N. meningitidis strains of serogroup B prior the administration of MenABCWY booster vaccination or placebo.
Pre vaccination is 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180).</description>
          <population>Analysis was done on the FAS Day 1 (Persistence) population. All subjects in the enrolled population who provided an evaluable serum sample at Day 1.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (N=51,38,36,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="O2" value="33" lower_limit="19" upper_limit="54"/>
                    <measurement group_id="O3" value="39" lower_limit="25" upper_limit="62"/>
                    <measurement group_id="O4" value="2.46" lower_limit="1.73" upper_limit="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (N=51,39,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" lower_limit="1.69" upper_limit="3.82"/>
                    <measurement group_id="O2" value="1.78" lower_limit="1.26" upper_limit="2.53"/>
                    <measurement group_id="O3" value="3.22" lower_limit="2.18" upper_limit="4.76"/>
                    <measurement group_id="O4" value="1.32" lower_limit="1.06" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (N=50,37,37,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="1.70" upper_limit="4.20"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.21" upper_limit="3.65"/>
                    <measurement group_id="O3" value="4.72" lower_limit="2.44" upper_limit="9.13"/>
                    <measurement group_id="O4" value="1.37" lower_limit="1.06" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (N=51,38,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="2.55" upper_limit="5.56"/>
                    <measurement group_id="O2" value="2.42" lower_limit="1.70" upper_limit="3.45"/>
                    <measurement group_id="O3" value="4.56" lower_limit="2.97" upper_limit="7.01"/>
                    <measurement group_id="O4" value="2.35" lower_limit="1.68" upper_limit="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (N=51,39,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="1.92" upper_limit="3.70"/>
                    <measurement group_id="O2" value="1.94" lower_limit="1.48" upper_limit="2.56"/>
                    <measurement group_id="O3" value="2.82" lower_limit="2.00" upper_limit="3.96"/>
                    <measurement group_id="O4" value="1.87" lower_limit="1.43" upper_limit="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=51,39,38,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" lower_limit="1.43" upper_limit="2.89"/>
                    <measurement group_id="O2" value="1.46" lower_limit="1.15" upper_limit="1.85"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.24" upper_limit="2.47"/>
                    <measurement group_id="O4" value="1.16" lower_limit="1.00" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.</title>
        <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y at Day 1 and Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.</description>
        <time_frame>Day 1 and Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>7. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.</title>
          <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y at Day 1 and Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.</description>
          <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1, N=25,25,16,22,11,21,19,16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="1.87" upper_limit="6.22"/>
                    <measurement group_id="O2" value="2.92" lower_limit="1.59" upper_limit="5.36"/>
                    <measurement group_id="O3" value="2.86" lower_limit="1.23" upper_limit="6.63"/>
                    <measurement group_id="O4" value="2.73" lower_limit="1.41" upper_limit="5.27"/>
                    <measurement group_id="O5" value="2.26" lower_limit="0.96" upper_limit="5.31"/>
                    <measurement group_id="O6" value="3.94" lower_limit="1.58" upper_limit="9.85"/>
                    <measurement group_id="O7" value="6.62" lower_limit="2.85" upper_limit="15"/>
                    <measurement group_id="O8" value="2.09" lower_limit="1.28" upper_limit="3.41"/>
                    <measurement group_id="O9" value="5.02" lower_limit="2.06" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 30, N=25,25,16,22,11,21,19,17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="174" upper_limit="383"/>
                    <measurement group_id="O2" value="4.28" lower_limit="2.03" upper_limit="9.03"/>
                    <measurement group_id="O3" value="333" lower_limit="199" upper_limit="559"/>
                    <measurement group_id="O4" value="3.07" lower_limit="1.51" upper_limit="6.25"/>
                    <measurement group_id="O5" value="438" lower_limit="287" upper_limit="670"/>
                    <measurement group_id="O6" value="416" lower_limit="198" upper_limit="871"/>
                    <measurement group_id="O7" value="138" lower_limit="84" upper_limit="229"/>
                    <measurement group_id="O8" value="46" lower_limit="24" upper_limit="87"/>
                    <measurement group_id="O9" value="4.91" lower_limit="2.00" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1, N=20,23,10,22,7,16,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="9.45" upper_limit="57"/>
                    <measurement group_id="O2" value="16" lower_limit="7.06" upper_limit="36"/>
                    <measurement group_id="O3" value="17" lower_limit="5.98" upper_limit="51"/>
                    <measurement group_id="O4" value="11" lower_limit="6.24" upper_limit="19"/>
                    <measurement group_id="O5" value="5.45" lower_limit="2.41" upper_limit="12"/>
                    <measurement group_id="O6" value="9.02" lower_limit="5.24" upper_limit="16"/>
                    <measurement group_id="O7" value="7.75" lower_limit="4.19" upper_limit="14"/>
                    <measurement group_id="O8" value="7.53" lower_limit="2.38" upper_limit="24"/>
                    <measurement group_id="O9" value="17" lower_limit="6.60" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 30, N=21,24,11,23,7,16,21,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="660" lower_limit="401" upper_limit="1084"/>
                    <measurement group_id="O2" value="17" lower_limit="7.60" upper_limit="38"/>
                    <measurement group_id="O3" value="612" lower_limit="245" upper_limit="1524"/>
                    <measurement group_id="O4" value="11" lower_limit="5.51" upper_limit="22"/>
                    <measurement group_id="O5" value="292" lower_limit="75" upper_limit="1142"/>
                    <measurement group_id="O6" value="135" lower_limit="69" upper_limit="261"/>
                    <measurement group_id="O7" value="338" lower_limit="205" upper_limit="558"/>
                    <measurement group_id="O8" value="304" lower_limit="124" upper_limit="742"/>
                    <measurement group_id="O9" value="20" lower_limit="7.20" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 1, N=20,24,13,21,11,19,18,17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="20" upper_limit="59"/>
                    <measurement group_id="O2" value="33" lower_limit="17" upper_limit="65"/>
                    <measurement group_id="O3" value="30" lower_limit="8.90" upper_limit="101"/>
                    <measurement group_id="O4" value="18" lower_limit="7.30" upper_limit="46"/>
                    <measurement group_id="O5" value="25" lower_limit="7.98" upper_limit="79"/>
                    <measurement group_id="O6" value="29" lower_limit="13" upper_limit="64"/>
                    <measurement group_id="O7" value="28" lower_limit="12" upper_limit="66"/>
                    <measurement group_id="O8" value="9.37" lower_limit="2.85" upper_limit="31"/>
                    <measurement group_id="O9" value="9.42" lower_limit="3.03" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 30, N=20,24,16,22,11,19,19,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="792" lower_limit="516" upper_limit="1216"/>
                    <measurement group_id="O2" value="34" lower_limit="16" upper_limit="71"/>
                    <measurement group_id="O3" value="880" lower_limit="671" upper_limit="1154"/>
                    <measurement group_id="O4" value="26" lower_limit="11" upper_limit="59"/>
                    <measurement group_id="O5" value="392" lower_limit="252" upper_limit="610"/>
                    <measurement group_id="O6" value="363" lower_limit="278" upper_limit="473"/>
                    <measurement group_id="O7" value="629" lower_limit="384" upper_limit="1032"/>
                    <measurement group_id="O8" value="364" lower_limit="180" upper_limit="736"/>
                    <measurement group_id="O9" value="16" lower_limit="4.87" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1, N=25,25,14,22,11,21,21,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4.89" upper_limit="21"/>
                    <measurement group_id="O2" value="15" lower_limit="5.50" upper_limit="43"/>
                    <measurement group_id="O3" value="15" lower_limit="4.33" upper_limit="53"/>
                    <measurement group_id="O4" value="5.66" lower_limit="2.25" upper_limit="14"/>
                    <measurement group_id="O5" value="2.4" lower_limit="1.05" upper_limit="5.47"/>
                    <measurement group_id="O6" value="1.84" lower_limit="1.07" upper_limit="3.14"/>
                    <measurement group_id="O7" value="6.43" lower_limit="2.86" upper_limit="14"/>
                    <measurement group_id="O8" value="5.79" lower_limit="1.77" upper_limit="19"/>
                    <measurement group_id="O9" value="5.32" lower_limit="1.81" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 30, N=25,25,16,23,11,21,21,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" lower_limit="294" upper_limit="734"/>
                    <measurement group_id="O2" value="16" lower_limit="5.65" upper_limit="48"/>
                    <measurement group_id="O3" value="697" lower_limit="435" upper_limit="1116"/>
                    <measurement group_id="O4" value="5.17" lower_limit="2.16" upper_limit="12"/>
                    <measurement group_id="O5" value="48" lower_limit="14" upper_limit="157"/>
                    <measurement group_id="O6" value="39" lower_limit="13" upper_limit="120"/>
                    <measurement group_id="O7" value="658" lower_limit="431" upper_limit="1003"/>
                    <measurement group_id="O8" value="419" lower_limit="217" upper_limit="809"/>
                    <measurement group_id="O9" value="6.36" lower_limit="1.91" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>8. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.</title>
        <description>The HT-hSBA GMTs against N. meningitidis strains of serogroups B at Day 1 and Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.</description>
        <time_frame>Day 1 and Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>8. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.</title>
          <description>The HT-hSBA GMTs against N. meningitidis strains of serogroups B at Day 1 and Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.</description>
          <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N=25,25,15,22,9,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="9.56" upper_limit="29"/>
                    <measurement group_id="O2" value="16" lower_limit="8.32" upper_limit="30"/>
                    <measurement group_id="O3" value="35" lower_limit="14" upper_limit="92"/>
                    <measurement group_id="O4" value="30" lower_limit="15" upper_limit="60"/>
                    <measurement group_id="O5" value="27" lower_limit="8.61" upper_limit="86"/>
                    <measurement group_id="O6" value="43" lower_limit="24" upper_limit="77"/>
                    <measurement group_id="O7" value="2.97" lower_limit="1.58" upper_limit="5.59"/>
                    <measurement group_id="O8" value="1.74" lower_limit="1.01" upper_limit="3.03"/>
                    <measurement group_id="O9" value="2.81" lower_limit="1.30" upper_limit="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N=25,25,17,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1131" lower_limit="716" upper_limit="1787"/>
                    <measurement group_id="O2" value="20" lower_limit="10" upper_limit="42"/>
                    <measurement group_id="O3" value="1598" lower_limit="900" upper_limit="2840"/>
                    <measurement group_id="O4" value="34" lower_limit="20" upper_limit="59"/>
                    <measurement group_id="O5" value="2205" lower_limit="1560" upper_limit="3117"/>
                    <measurement group_id="O6" value="2576" lower_limit="1716" upper_limit="3867"/>
                    <measurement group_id="O7" value="28" lower_limit="11" upper_limit="67"/>
                    <measurement group_id="O8" value="30" lower_limit="11" upper_limit="78"/>
                    <measurement group_id="O9" value="3.41" lower_limit="1.20" upper_limit="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N= 25,25,16,22,11,21,19,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="1.50" upper_limit="5.67"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.23" upper_limit="3.34"/>
                    <measurement group_id="O3" value="1.46" lower_limit="0.96" upper_limit="2.21"/>
                    <measurement group_id="O4" value="1.92" lower_limit="1.11" upper_limit="3.32"/>
                    <measurement group_id="O5" value="3.45" lower_limit="1.81" upper_limit="6.57"/>
                    <measurement group_id="O6" value="3.24" lower_limit="1.76" upper_limit="5.94"/>
                    <measurement group_id="O7" value="1.09" lower_limit="0.96" upper_limit="1.22"/>
                    <measurement group_id="O8" value="1.47" lower_limit="0.92" upper_limit="2.36"/>
                    <measurement group_id="O9" value="1.18" lower_limit="0.97" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, 25,25,17,23,11,21,19,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="60" upper_limit="157"/>
                    <measurement group_id="O2" value="2.36" lower_limit="1.39" upper_limit="4.01"/>
                    <measurement group_id="O3" value="56" lower_limit="32" upper_limit="97"/>
                    <measurement group_id="O4" value="2.54" lower_limit="1.42" upper_limit="4.53"/>
                    <measurement group_id="O5" value="132" lower_limit="64" upper_limit="271"/>
                    <measurement group_id="O6" value="79" lower_limit="42" upper_limit="149"/>
                    <measurement group_id="O7" value="5.27" lower_limit="2.54" upper_limit="11"/>
                    <measurement group_id="O8" value="3.85" lower_limit="1.85" upper_limit="8.02"/>
                    <measurement group_id="O9" value="1.63" lower_limit="0.75" upper_limit="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N=24,25,15,20,10,21,20,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" lower_limit="1.3" upper_limit="3.98"/>
                    <measurement group_id="O2" value="3.11" lower_limit="1.44" upper_limit="6.68"/>
                    <measurement group_id="O3" value="2.67" lower_limit="0.87" upper_limit="8.24"/>
                    <measurement group_id="O4" value="1.36" lower_limit="0.83" upper_limit="2.23"/>
                    <measurement group_id="O5" value="2.46" lower_limit="0.72" upper_limit="8.4"/>
                    <measurement group_id="O6" value="6.81" lower_limit="2.47" upper_limit="19"/>
                    <measurement group_id="O7" value="1.34" lower_limit="0.84" upper_limit="2.13"/>
                    <measurement group_id="O8" value="1.23" lower_limit="0.88" upper_limit="1.71"/>
                    <measurement group_id="O9" value="1.63" lower_limit="0.86" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 30, N=25,25,17,22,11,21,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685" lower_limit="397" upper_limit="1182"/>
                    <measurement group_id="O2" value="3.21" lower_limit="1.4" upper_limit="7.37"/>
                    <measurement group_id="O3" value="856" lower_limit="454" upper_limit="1614"/>
                    <measurement group_id="O4" value="1.94" lower_limit="1.02" upper_limit="3.69"/>
                    <measurement group_id="O5" value="1336" lower_limit="810" upper_limit="2202"/>
                    <measurement group_id="O6" value="1275" lower_limit="794" upper_limit="2048"/>
                    <measurement group_id="O7" value="3.5" lower_limit="1.32" upper_limit="9.3"/>
                    <measurement group_id="O8" value="3.42" lower_limit="1.19" upper_limit="9.8"/>
                    <measurement group_id="O9" value="1.76" lower_limit="0.75" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1, N= 25,25,15,22,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" lower_limit="2.09" upper_limit="5.95"/>
                    <measurement group_id="O2" value="3.54" lower_limit="1.98" upper_limit="6.31"/>
                    <measurement group_id="O3" value="2.16" lower_limit="1.15" upper_limit="4.08"/>
                    <measurement group_id="O4" value="2.52" lower_limit="1.58" upper_limit="4.03"/>
                    <measurement group_id="O5" value="4.10" lower_limit="1.89" upper_limit="8.90"/>
                    <measurement group_id="O6" value="6.08" lower_limit="3.18" upper_limit="12"/>
                    <measurement group_id="O7" value="2.08" lower_limit="1.26" upper_limit="3.42"/>
                    <measurement group_id="O8" value="2.06" lower_limit="1.13" upper_limit="3.77"/>
                    <measurement group_id="O9" value="3.01" lower_limit="1.38" upper_limit="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30, N=25,25,17,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="31" upper_limit="79"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2.02" upper_limit="6.64"/>
                    <measurement group_id="O3" value="29" lower_limit="14" upper_limit="58"/>
                    <measurement group_id="O4" value="2.48" lower_limit="1.55" upper_limit="3.96"/>
                    <measurement group_id="O5" value="68" lower_limit="33" upper_limit="142"/>
                    <measurement group_id="O6" value="69" lower_limit="36" upper_limit="129"/>
                    <measurement group_id="O7" value="3.26" lower_limit="1.75" upper_limit="6.06"/>
                    <measurement group_id="O8" value="2.15" lower_limit="1.13" upper_limit="4.07"/>
                    <measurement group_id="O9" value="3.86" lower_limit="1.40" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N=25,25,15,23,11,21,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="1.57" upper_limit="4.22"/>
                    <measurement group_id="O2" value="2.58" lower_limit="1.62" upper_limit="4.12"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.97" upper_limit="2.65"/>
                    <measurement group_id="O4" value="2.27" lower_limit="1.61" upper_limit="3.2"/>
                    <measurement group_id="O5" value="3.11" lower_limit="1.74" upper_limit="5.56"/>
                    <measurement group_id="O6" value="3.18" lower_limit="1.87" upper_limit="5.41"/>
                    <measurement group_id="O7" value="1.91" lower_limit="1.14" upper_limit="3.2"/>
                    <measurement group_id="O8" value="1.45" lower_limit="1.03" upper_limit="2.05"/>
                    <measurement group_id="O9" value="2.37" lower_limit="1.31" upper_limit="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N=25,25,17,23,11,21,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="18" upper_limit="54"/>
                    <measurement group_id="O2" value="2.18" lower_limit="1.39" upper_limit="3.42"/>
                    <measurement group_id="O3" value="20" lower_limit="11" upper_limit="37"/>
                    <measurement group_id="O4" value="2.33" lower_limit="1.62" upper_limit="3.35"/>
                    <measurement group_id="O5" value="56" lower_limit="27" upper_limit="117"/>
                    <measurement group_id="O6" value="35" lower_limit="21" upper_limit="58"/>
                    <measurement group_id="O7" value="3.44" lower_limit="2.05" upper_limit="5.75"/>
                    <measurement group_id="O8" value="2.57" lower_limit="1.51" upper_limit="4.37"/>
                    <measurement group_id="O9" value="2.93" lower_limit="1.14" upper_limit="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N= 25,25,15,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.09" upper_limit="2.48"/>
                    <measurement group_id="O2" value="2.11" lower_limit="1.28" upper_limit="3.49"/>
                    <measurement group_id="O3" value="1.32" lower_limit="0.94" upper_limit="1.84"/>
                    <measurement group_id="O4" value="1.58" lower_limit="1.11" upper_limit="2.27"/>
                    <measurement group_id="O5" value="1.72" lower_limit="0.99" upper_limit="2.98"/>
                    <measurement group_id="O6" value="2.07" lower_limit="1.17" upper_limit="3.66"/>
                    <measurement group_id="O7" value="1.18" lower_limit="0.84" upper_limit="1.66"/>
                    <measurement group_id="O8" value="1.18" lower_limit="0.90" upper_limit="1.54"/>
                    <measurement group_id="O9" value="1.12" lower_limit="0.94" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N= 25,25,17,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="18" upper_limit="47"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.21" upper_limit="3.40"/>
                    <measurement group_id="O3" value="12" lower_limit="5.04" upper_limit="31"/>
                    <measurement group_id="O4" value="1.87" lower_limit="1.11" upper_limit="3.16"/>
                    <measurement group_id="O5" value="17" lower_limit="6.22" upper_limit="45"/>
                    <measurement group_id="O6" value="28" lower_limit="17" upper_limit="44"/>
                    <measurement group_id="O7" value="2.48" lower_limit="1.31" upper_limit="4.69"/>
                    <measurement group_id="O8" value="1.58" lower_limit="0.96" upper_limit="2.59"/>
                    <measurement group_id="O9" value="1.71" lower_limit="0.84" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.</title>
        <description>Percentage of subjects with four-fold rise in HT-hSBA titers against N. meningitidis serogroup B strains, from Day 1 (baseline) to Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.
Four-fold rise is defined as follows: for subjects with a pre-vaccination titer &lt; 1:2, a post-titer of ≥ 1:8; for subjects with a pre-vaccination titer ≥ 1:2 at least a four-fold increase.</description>
        <time_frame>Day 1 and Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>9. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.</title>
          <description>Percentage of subjects with four-fold rise in HT-hSBA titers against N. meningitidis serogroup B strains, from Day 1 (baseline) to Day 30 (one month) after the administration of MenABCWY booster vaccination or placebo.
Four-fold rise is defined as follows: for subjects with a pre-vaccination titer &lt; 1:2, a post-titer of ≥ 1:8; for subjects with a pre-vaccination titer ≥ 1:2 at least a four-fold increase.</description>
          <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N= 24,24,16,22,11,20,6,5,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="78.9" upper_limit="99.89"/>
                    <measurement group_id="O2" value="100" lower_limit="85.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O4" value="100" lower_limit="84.6" upper_limit="100.0"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N=25,25,15,22,9,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="4" lower_limit="0.10" upper_limit="20.4"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O5" value="100" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O7" value="57" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O8" value="79" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N=24,25,16,23,11,20,6,5,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="85.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96" lower_limit="79.6" upper_limit="99.90"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="96" lower_limit="78.1" upper_limit="99.89"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="90" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, N=25,25,16,22,11,21,19,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="63.9" upper_limit="95.5"/>
                    <measurement group_id="O2" value="4" lower_limit="0.10" upper_limit="20.4"/>
                    <measurement group_id="O3" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O7" value="37" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O8" value="26" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N=23,23,16,20,11,20,6,5,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="56.3" upper_limit="92.5"/>
                    <measurement group_id="O2" value="74" lower_limit="51.6" upper_limit="89.8"/>
                    <measurement group_id="O3" value="63" lower_limit="35.4" upper_limit="84.8"/>
                    <measurement group_id="O4" value="75" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day30,N=24,25,15,20,10,21,20,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="85.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="4" lower_limit="0.10" upper_limit="20.4"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O5" value="100" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="90" lower_limit="69.6" upper_limit="98.8"/>
                    <measurement group_id="O7" value="20" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O8" value="22" lower_limit="6.4" upper_limit="47.6"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1, N=24,23,16,21,11,20,6,5,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="9.8" upper_limit="46.7"/>
                    <measurement group_id="O2" value="17" lower_limit="5.0" upper_limit="38.8"/>
                    <measurement group_id="O3" value="31" lower_limit="11.0" upper_limit="58.7"/>
                    <measurement group_id="O4" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="55" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30,N=25,25,15,22,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="54.9" upper_limit="90.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="13.7"/>
                    <measurement group_id="O3" value="87" lower_limit="59.5" upper_limit="98.3"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O7" value="14" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N=24,25,16,22,11,20,6,5,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="32.8" upper_limit="74.4"/>
                    <measurement group_id="O2" value="48" lower_limit="27.8" upper_limit="68.7"/>
                    <measurement group_id="O3" value="63" lower_limit="35.4" upper_limit="84.8"/>
                    <measurement group_id="O4" value="59" lower_limit="36.4" upper_limit="79.3"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N=25,25,15,23,11,21,5,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="50.6" upper_limit="87.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="13.7"/>
                    <measurement group_id="O3" value="87" lower_limit="59.5" upper_limit="98.3"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O7" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O8" value="5" lower_limit="0.13" upper_limit="26.0"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N=24,24,16,22,11,20,6,5,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="29.1" upper_limit="70.9"/>
                    <measurement group_id="O2" value="46" lower_limit="25.6" upper_limit="67.2"/>
                    <measurement group_id="O3" value="50" lower_limit="24.7" upper_limit="75.3"/>
                    <measurement group_id="O4" value="59" lower_limit="36.4" upper_limit="79.3"/>
                    <measurement group_id="O5" value="55" lower_limit="23.4" upper_limit="83.3"/>
                    <measurement group_id="O6" value="70" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N=25,25,15,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="54.9" upper_limit="90.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="13.7"/>
                    <measurement group_id="O3" value="67" lower_limit="38.4" upper_limit="88.2"/>
                    <measurement group_id="O4" value="4" lower_limit="0.11" upper_limit="21.9"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="67" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="5" lower_limit="0.13" upper_limit="26.0"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>10. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 Against N. Meningitidis Serogroups A,C,W,Y.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 to N. meningitidis serogroups A,C,W,Y at Day 1 and Day 30 (one month) after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
        <time_frame>Day 1 and Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>10. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 Against N. Meningitidis Serogroups A,C,W,Y.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 to N. meningitidis serogroups A,C,W,Y at Day 1 and Day 30 (one month) after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
          <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1, N=25,25,16,22,11,21,19,16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="14.9" upper_limit="53.5"/>
                    <measurement group_id="O2" value="20" lower_limit="6.8" upper_limit="40.7"/>
                    <measurement group_id="O3" value="19" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O4" value="27" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O5" value="27" lower_limit="6.0" upper_limit="61.0"/>
                    <measurement group_id="O6" value="33" lower_limit="14.6" upper_limit="57.0"/>
                    <measurement group_id="O7" value="47" lower_limit="24.4" upper_limit="71.1"/>
                    <measurement group_id="O8" value="6" lower_limit="0.16" upper_limit="30.2"/>
                    <measurement group_id="O9" value="39" lower_limit="17.3" upper_limit="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 30, N=25,25,16,22,11,21,19,17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100"/>
                    <measurement group_id="O2" value="36" lower_limit="18" upper_limit="57.5"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="27" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O6" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O8" value="94" lower_limit="71.3" upper_limit="99.85"/>
                    <measurement group_id="O9" value="39" lower_limit="17.3" upper_limit="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1, N=20,23,10,22,7,16,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O2" value="65" lower_limit="42.7" upper_limit="83.6"/>
                    <measurement group_id="O3" value="70" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O4" value="68" lower_limit="45.1" upper_limit="86.1"/>
                    <measurement group_id="O5" value="43" lower_limit="9.9" upper_limit="81.6"/>
                    <measurement group_id="O6" value="63" lower_limit="35.4" upper_limit="84.8"/>
                    <measurement group_id="O7" value="57" lower_limit="34" upper_limit="78.2"/>
                    <measurement group_id="O8" value="44" lower_limit="21.5" upper_limit="69.2"/>
                    <measurement group_id="O9" value="65" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 30, N=21,24,11,23,7,16,21,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="63" lower_limit="40.6" upper_limit="81.2"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="61" lower_limit="38.5" upper_limit="80.3"/>
                    <measurement group_id="O5" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="61" lower_limit="35.7" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 1, N=20,24,13,21,11,19,18,17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O2" value="88" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O3" value="77" lower_limit="46.2" upper_limit="95"/>
                    <measurement group_id="O4" value="71" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="79" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O7" value="83" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O8" value="53" lower_limit="27.8" upper_limit="77"/>
                    <measurement group_id="O9" value="53" lower_limit="26.6" upper_limit="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 30, N=20,24,16,22,11,19,19,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O2" value="79" lower_limit="57.8" upper_limit="92.9"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="77" lower_limit="54.6" upper_limit="92.9"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O9" value="63" lower_limit="35.4" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1, N=25,25,14,22,11,21,21,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="42.5" upper_limit="82"/>
                    <measurement group_id="O2" value="64" lower_limit="42.5" upper_limit="82"/>
                    <measurement group_id="O3" value="64" lower_limit="35.1" upper_limit="87.2"/>
                    <measurement group_id="O4" value="41" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="10" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O7" value="52" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O8" value="39" lower_limit="17.3" upper_limit="64.3"/>
                    <measurement group_id="O9" value="39" lower_limit="17.3" upper_limit="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 30, N=25,25,16,23,11,21,21,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100"/>
                    <measurement group_id="O2" value="60" lower_limit="38.7" upper_limit="78.9"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="39" lower_limit="19.7" upper_limit="61.5"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O7" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O9" value="39" lower_limit="17.3" upper_limit="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>11. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 Against N. Meningitidis Serogroup B Strains.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 to N. meningitidis serogroup B strains at Day 1 and Day 30 (one month) after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
        <time_frame>Day 1 and Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>11. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 Against N. Meningitidis Serogroup B Strains.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 to N. meningitidis serogroup B strains at Day 1 and Day 30 (one month) after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
          <population>Analysis was done on FAS Day 30 (Booster) population.. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N=25,25,15,22,9,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="54.9" upper_limit="90.6"/>
                    <measurement group_id="O2" value="76" lower_limit="54.9" upper_limit="90.6"/>
                    <measurement group_id="O3" value="87" lower_limit="59.5" upper_limit="98.3"/>
                    <measurement group_id="O4" value="86" lower_limit="65.1" upper_limit="97.1"/>
                    <measurement group_id="O5" value="89" lower_limit="51.8" upper_limit="99.72"/>
                    <measurement group_id="O6" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="16" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O9" value="22" lower_limit="6.4" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N=25,25,17,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100"/>
                    <measurement group_id="O2" value="84" lower_limit="63.9" upper_limit="95.5"/>
                    <measurement group_id="O3" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O4" value="91" lower_limit="72" upper_limit="98.6"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O7" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O8" value="84" lower_limit="60.4" upper_limit="96.6"/>
                    <measurement group_id="O9" value="22" lower_limit="6.4" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N=25,25,16,22,11,21,19,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="4.5" upper_limit="36.1"/>
                    <measurement group_id="O2" value="24" lower_limit="9.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="13" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O4" value="18" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="29" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="17.6"/>
                    <measurement group_id="O8" value="5" lower_limit="0.13" upper_limit="26.0"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, N=25,25,17,23,11,21,19,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="79.6" upper_limit="99.90"/>
                    <measurement group_id="O2" value="24" lower_limit="9.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O4" value="26" lower_limit="10.2" upper_limit="48.4"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O7" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O8" value="32" lower_limit="12.6" upper_limit="56.6"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N=24,25,15,20,10,21,20,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="9.8" upper_limit="46.7"/>
                    <measurement group_id="O2" value="24" lower_limit="9.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="20" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O4" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O5" value="20" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O6" value="43" lower_limit="21.8" upper_limit="66"/>
                    <measurement group_id="O7" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O8" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O9" value="11" lower_limit="1.4" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 30, N=25,25,17,22,11,21,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100"/>
                    <measurement group_id="O2" value="24" lower_limit="9.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O4" value="18" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O7" value="25" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O8" value="26" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O9" value="11" lower_limit="1.4" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1,N=25,25,15,22,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="18.0" upper_limit="57.5"/>
                    <measurement group_id="O2" value="36" lower_limit="18.0" upper_limit="57.5"/>
                    <measurement group_id="O3" value="27" lower_limit="7.8" upper_limit="55.1"/>
                    <measurement group_id="O4" value="27" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O5" value="64" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O6" value="52" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="16" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O9" value="33" lower_limit="13.3" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30,N=25,25,17,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86.3" upper_limit="100"/>
                    <measurement group_id="O2" value="40" lower_limit="21.1" upper_limit="61.3"/>
                    <measurement group_id="O3" value="88" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O4" value="30" lower_limit="13.2" upper_limit="52.9"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O7" value="33" lower_limit="14.6" upper_limit="57.0"/>
                    <measurement group_id="O8" value="21" lower_limit="6.1" upper_limit="45.6"/>
                    <measurement group_id="O9" value="33" lower_limit="13.3" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N=25,25,15,23,11,21,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="9.4" upper_limit="45.1"/>
                    <measurement group_id="O2" value="32" lower_limit="14.9" upper_limit="53.5"/>
                    <measurement group_id="O3" value="7" lower_limit="0.17" upper_limit="31.9"/>
                    <measurement group_id="O4" value="17" lower_limit="5.0" upper_limit="38.8"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="29" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O7" value="10" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O8" value="11" lower_limit="1.3" upper_limit="33.1"/>
                    <measurement group_id="O9" value="22" lower_limit="6.4" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N=25,25,17,23,11,21,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="74" upper_limit="99"/>
                    <measurement group_id="O2" value="28" lower_limit="12.1" upper_limit="49.4"/>
                    <measurement group_id="O3" value="88" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O4" value="30" lower_limit="13.2" upper_limit="52.9"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O6" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O7" value="35" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O8" value="32" lower_limit="12.6" upper_limit="56.6"/>
                    <measurement group_id="O9" value="22" lower_limit="6.4" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N=25,25,15,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="4.5" upper_limit="36.1"/>
                    <measurement group_id="O2" value="28" lower_limit="12.1" upper_limit="49.4"/>
                    <measurement group_id="O3" value="7" lower_limit="0.17" upper_limit="31.9"/>
                    <measurement group_id="O4" value="9" lower_limit="1.1" upper_limit="28"/>
                    <measurement group_id="O5" value="9" lower_limit="0.23" upper_limit="41.3"/>
                    <measurement group_id="O6" value="24" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O7" value="5" lower_limit="0.12" upper_limit="23.8"/>
                    <measurement group_id="O8" value="5" lower_limit="0.13" upper_limit="26"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N=25,25,17,23,11,21,21,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="74" upper_limit="99"/>
                    <measurement group_id="O2" value="20" lower_limit="6.8" upper_limit="40.7"/>
                    <measurement group_id="O3" value="71" lower_limit="44" upper_limit="89.7"/>
                    <measurement group_id="O4" value="13" lower_limit="2.8" upper_limit="33.6"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="16" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12. Percentage of Subjects With Seroresponse to N. Meningitidis Serogroups A, C, W and Y, at Day 30 After Booster Vaccination in This Study.</title>
        <description>Percentage of subjects with seroresponse to N. meningitidis serogroup A, C, W and Y, at Day 30 after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
        <time_frame>Day 30</time_frame>
        <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>12. Percentage of Subjects With Seroresponse to N. Meningitidis Serogroups A, C, W and Y, at Day 30 After Booster Vaccination in This Study.</title>
          <description>Percentage of subjects with seroresponse to N. meningitidis serogroup A, C, W and Y, at Day 30 after the administration of a booster dose of MenABCWY vaccine or placebo in this study, versus baseline.</description>
          <population>Analysis was done on FAS Day 30 (Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 30 (for seroresponse, Day 1 and Day 30 samples were required).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="79.6" upper_limit="99.90"/>
                    <measurement group_id="O2" value="12" lower_limit="2.5" upper_limit="31.2"/>
                    <measurement group_id="O3" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="15.4"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="86" lower_limit="63.7" upper_limit="97"/>
                    <measurement group_id="O7" value="84" lower_limit="60.4" upper_limit="96.6"/>
                    <measurement group_id="O8" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O2" value="4" lower_limit="0.11" upper_limit="21.9"/>
                    <measurement group_id="O3" value="100" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="15.4"/>
                    <measurement group_id="O5" value="100" lower_limit="59.0" upper_limit="100.0"/>
                    <measurement group_id="O6" value="81" lower_limit="54.4" upper_limit="96.0"/>
                    <measurement group_id="O7" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O8" value="78" lower_limit="52.4" upper_limit="93.6"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O2" value="4" lower_limit="0.11" upper_limit="21.1"/>
                    <measurement group_id="O3" value="85" lower_limit="54.6" upper_limit="98.1"/>
                    <measurement group_id="O4" value="5" lower_limit="0.12" upper_limit="23.8"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="68" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O7" value="83" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O8" value="76" lower_limit="50.1" upper_limit="93.2"/>
                    <measurement group_id="O9" value="20" lower_limit="4.3" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="4" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O3" value="100" lower_limit="76.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="15.4"/>
                    <measurement group_id="O5" value="73" lower_limit="39" upper_limit="94"/>
                    <measurement group_id="O6" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O7" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>13. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 against N. meningitidis serogroups A, C, W, Y, at 24 and 36 months after the primary vaccination.</description>
        <time_frame>Day 1 and Day 365</time_frame>
        <population>Analysis was done on the FAS Day 365 (Persistence of Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>13. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 against N. meningitidis serogroups A, C, W, Y, at 24 and 36 months after the primary vaccination.</description>
          <population>Analysis was done on the FAS Day 365 (Persistence of Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1, N= 21,22,15,20,10,20,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="18" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O4" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O5" value="30" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O6" value="35" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O7" value="45" lower_limit="23.1" upper_limit="68.5"/>
                    <measurement group_id="O8" value="12" lower_limit="1.5" upper_limit="36.4"/>
                    <measurement group_id="O9" value="41" lower_limit="18.4" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 365, N= 21,22,16,20,10,20,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O2" value="23" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="88" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O4" value="25" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O5" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O6" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O7" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O8" value="50" lower_limit="26.0" upper_limit="74.0"/>
                    <measurement group_id="O9" value="35" lower_limit="14.2" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1, N= 20,19,14,20,11,19,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O2" value="68" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O3" value="71" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O7" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O8" value="50" lower_limit="26" upper_limit="74"/>
                    <measurement group_id="O9" value="75" lower_limit="47.6" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 365, N= 21,21,16,20,11,19,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="50" lower_limit="27.2" upper_limit="72.8"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="95" lower_limit="74" upper_limit="99.87"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="65" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 1, N= 20,22,12,20,11,20,17,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O2" value="95" lower_limit="77.2" upper_limit="99.88"/>
                    <measurement group_id="O3" value="75" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O4" value="70" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O7" value="82" lower_limit="56.6" upper_limit="96.2"/>
                    <measurement group_id="O8" value="61" lower_limit="35.7" upper_limit="82.7"/>
                    <measurement group_id="O9" value="56" lower_limit="29.9" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 365, N= 21,22,16,20,11,20,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="82" lower_limit="59.7" upper_limit="94.8"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O9" value="65" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1, N= 21,21,14,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O2" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O3" value="71" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="11" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O7" value="55" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O8" value="44" lower_limit="21.5" upper_limit="69.2"/>
                    <measurement group_id="O9" value="41" lower_limit="18.4" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 365, N= 21,21,16,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="52" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="72" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O7" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="47" lower_limit="23" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>14. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitidis strains of serogroup B, at 24 and 36 months after the primary vaccination.</description>
        <time_frame>Day 1, Day 30 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>14. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitidis strains of serogroup B, at 24 and 36 months after the primary vaccination.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N=21,22,14,20,9,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O2" value="82" lower_limit="59.7" upper_limit="94.8"/>
                    <measurement group_id="O3" value="86" lower_limit="57.2" upper_limit="98.2"/>
                    <measurement group_id="O4" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O5" value="89" lower_limit="51.8" upper_limit="99.72"/>
                    <measurement group_id="O6" value="95" lower_limit="74.0" upper_limit="99.87"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="17" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O9" value="24" lower_limit="6.8" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N=21,22,16,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="86" lower_limit="65.1" upper_limit="97.1"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="90" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O7" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O8" value="83" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O9" value="25" lower_limit="7.3" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 365, N=21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="77" lower_limit="54.6" upper_limit="92.2"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="80" lower_limit="56.3" upper_limit="94.3"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O7" value="43" lower_limit="21.8" upper_limit="66.0"/>
                    <measurement group_id="O8" value="33" lower_limit="13.3" upper_limit="59.0"/>
                    <measurement group_id="O9" value="18" lower_limit="3.8" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N=21,22,15,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O2" value="27" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="13" lower_limit="1.7" upper_limit="40.5"/>
                    <measurement group_id="O4" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O7" value="5" lower_limit="0.12" upper_limit="23.8"/>
                    <measurement group_id="O8" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, N=21,22,16,20,11,20,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="27" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O8" value="33" lower_limit="13.3" upper_limit="59.0"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 365, N=21,22,16,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O2" value="18" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="44" lower_limit="19.8" upper_limit="70.1"/>
                    <measurement group_id="O4" value="10" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="11" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N=21,22,14,18,10,19,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O2" value="27" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="21" lower_limit="4.7" upper_limit="50.8"/>
                    <measurement group_id="O4" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O5" value="20" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O6" value="42" lower_limit="20.3" upper_limit="66.5"/>
                    <measurement group_id="O7" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O8" value="6" lower_limit="0.15" upper_limit="28.7"/>
                    <measurement group_id="O9" value="12" lower_limit="1.5" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 30, N=21,22,16,17,11,19,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="27" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="6" lower_limit="0.15" upper_limit="28.7"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O7" value="21" lower_limit="6.1" upper_limit="45.6"/>
                    <measurement group_id="O8" value="28" lower_limit="9.7" upper_limit="53.5"/>
                    <measurement group_id="O9" value="13" lower_limit="1.6" upper_limit="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364(Day 365, N=21,22,16,18,11,19,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O2" value="32" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="75" lower_limit="47.6" upper_limit="92.7"/>
                    <measurement group_id="O4" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="95" lower_limit="74.0" upper_limit="99.87"/>
                    <measurement group_id="O7" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O8" value="11" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O9" value="18" lower_limit="3.8" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1, N=21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="41" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="29" lower_limit="8.4" upper_limit="58.1"/>
                    <measurement group_id="O4" value="25" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O5" value="64" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O6" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="17" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O9" value="35" lower_limit="14.2" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30, N=21,22,16,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="45" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O3" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O4" value="25" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="95" lower_limit="74.0" upper_limit="99.87"/>
                    <measurement group_id="O7" value="33" lower_limit="14.6" upper_limit="57.0"/>
                    <measurement group_id="O8" value="22" lower_limit="6.4" upper_limit="47.6"/>
                    <measurement group_id="O9" value="38" lower_limit="15.2" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084(Day 365, N=21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O2" value="32" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="50" lower_limit="24.7" upper_limit="75.3"/>
                    <measurement group_id="O4" value="20" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="74" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O7" value="29" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O8" value="17" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O9" value="35" lower_limit="14.2" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N=21,22,14,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O2" value="36" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O3" value="7" lower_limit="0.18" upper_limit="33.9"/>
                    <measurement group_id="O4" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O7" value="10" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O8" value="11" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O9" value="24" lower_limit="6.8" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N=21,22,16,20,11,20,20,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="32" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="88" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O4" value="20" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O7" value="35" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O8" value="33" lower_limit="13.3" upper_limit="59.0"/>
                    <measurement group_id="O9" value="25" lower_limit="7.3" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 365, N=21,22,16,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O2" value="18" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="38" lower_limit="15.2" upper_limit="64.6"/>
                    <measurement group_id="O4" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O7" value="14" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O8" value="11" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O9" value="24" lower_limit="6.8" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N=21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O2" value="32" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="7" lower_limit="0.18" upper_limit="33.9"/>
                    <measurement group_id="O4" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O5" value="9" lower_limit="0.23" upper_limit="41.3"/>
                    <measurement group_id="O6" value="26" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O7" value="5" lower_limit="0.12" upper_limit="23.8"/>
                    <measurement group_id="O8" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N=21,22,16,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="23" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="75" lower_limit="47.6" upper_limit="92.7"/>
                    <measurement group_id="O4" value="10" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="95" lower_limit="74.0" upper_limit="99.87"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="17" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 365, N=21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O2" value="14" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="31" lower_limit="11.0" upper_limit="58.7"/>
                    <measurement group_id="O4" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="42" lower_limit="20.3" upper_limit="66.5"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>15. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.</title>
        <description>Percentage of subjects with four-fold rise in HT-hSBA titers against N. meningitidis serogroup B strains, at 24 and 36 months after the primary vaccination.
Four-fold rise is defined as follows: for subjects with a pre-vaccination titer &lt; 1:2, a post-titer of ≥ 1:8; for subjects with a pre-vaccination titer ≥ 1:2 at least a four-fold increase.</description>
        <time_frame>Day 1, Day 30 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>15. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.</title>
          <description>Percentage of subjects with four-fold rise in HT-hSBA titers against N. meningitidis serogroup B strains, at 24 and 36 months after the primary vaccination.
Four-fold rise is defined as follows: for subjects with a pre-vaccination titer &lt; 1:2, a post-titer of ≥ 1:8; for subjects with a pre-vaccination titer ≥ 1:2 at least a four-fold increase.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N= 20,21,15,19,11,18,6,4,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O2" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="94" lower_limit="72.7" upper_limit="99.86"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N=21,22,14,20,9,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="5" lower_limit="0.12" upper_limit="22.8"/>
                    <measurement group_id="O3" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="100" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O7" value="57" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O8" value="78" lower_limit="52.4" upper_limit="93.6"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 365, N=21,22,14,20,9,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O2" value="5" lower_limit="0.12" upper_limit="22.8"/>
                    <measurement group_id="O3" value="86" lower_limit="57.2" upper_limit="98.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="89" lower_limit="51.8" upper_limit="99.72"/>
                    <measurement group_id="O6" value="74" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O7" value="29" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O8" value="28" lower_limit="9.7" upper_limit="53.5"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N=20,22,15,20,11,19,6,4,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="95" lower_limit="77.2" upper_limit="99.88"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="89" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, N=21,22,15,20,11,20,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="5" lower_limit="0.12" upper_limit="22.8"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O7" value="37" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O8" value="28" lower_limit="9.7" upper_limit="53.5"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 365, N=21,22,15,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="20" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="64" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O6" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O7" value="10" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N=19,21,15,15,11,18,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O2" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O3" value="67" lower_limit="38.4" upper_limit="88.2"/>
                    <measurement group_id="O4" value="67" lower_limit="38.4" upper_limit="88.2"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 30, N=21,22,14,17,10,19,19,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="5" lower_limit="0.12" upper_limit="22.8"/>
                    <measurement group_id="O3" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O4" value="6" lower_limit="0.15" upper_limit="28.7"/>
                    <measurement group_id="O5" value="100" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="89" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O7" value="16" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O8" value="24" lower_limit="6.8" upper_limit="49.9"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 365,N=21,22,14,18,10,19,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O2" value="5" lower_limit="0.12" upper_limit="22.8"/>
                    <measurement group_id="O3" value="64" lower_limit="35.1" upper_limit="87.2"/>
                    <measurement group_id="O4" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O5" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O6" value="79" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O7" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O8" value="6" lower_limit="0.15" upper_limit="28.7"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1, N=20,20,15,18,11,18,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O2" value="20" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O3" value="33" lower_limit="11.8" upper_limit="61.6"/>
                    <measurement group_id="O4" value="17" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="56" lower_limit="30.8" upper_limit="78.5"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30, N=21,22,14,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O7" value="14" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 365,N=21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="23.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="27" lower_limit="6.0" upper_limit="61.0"/>
                    <measurement group_id="O6" value="5" lower_limit="0.13" upper_limit="26.0"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N=20,22,15,19,11,19,6,4,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O2" value="55" lower_limit="32.2" upper_limit="75.6"/>
                    <measurement group_id="O3" value="67" lower_limit="38.4" upper_limit="88.2"/>
                    <measurement group_id="O4" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="63" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N=21,22,14,20,11,20,20,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="86" lower_limit="57.2" upper_limit="98.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O7" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O8" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 365, N=21,22,14,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="23.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="25" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O7" value="10" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N=20,21,15,19,11,18,6,4,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O2" value="52" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O3" value="53" lower_limit="26.6" upper_limit="78.7"/>
                    <measurement group_id="O4" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O5" value="55" lower_limit="23.4" upper_limit="83.3"/>
                    <measurement group_id="O6" value="67" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N=21,22,14,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="71" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="63" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O7" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="6" lower_limit="0.14" upper_limit="27.3"/>
                    <measurement group_id="O9" value="6" lower_limit="0.16" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 365, N=21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="14" lower_limit="1.8" upper_limit="42.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="9" lower_limit="0.23" upper_limit="41.3"/>
                    <measurement group_id="O6" value="5" lower_limit="0.13" upper_limit="26.0"/>
                    <measurement group_id="O7" value="10" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O9" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>16. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.</title>
        <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y, at 24 and 36 months after the primary vaccination.</description>
        <time_frame>Day 1 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>16. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.</title>
          <description>The HT-hSBA GMTs against N. meningitidis serogroup A, C, W, Y, at 24 and 36 months after the primary vaccination.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1, N=21,22,15,20,10,20,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="1.98" upper_limit="8"/>
                    <measurement group_id="O2" value="2.73" lower_limit="1.44" upper_limit="5.15"/>
                    <measurement group_id="O3" value="3.07" lower_limit="1.26" upper_limit="7.47"/>
                    <measurement group_id="O4" value="2.98" lower_limit="1.38" upper_limit="6.42"/>
                    <measurement group_id="O5" value="2.27" lower_limit="0.87" upper_limit="5.94"/>
                    <measurement group_id="O6" value="4.22" lower_limit="1.63" upper_limit="11"/>
                    <measurement group_id="O7" value="6.31" lower_limit="2.82" upper_limit="14"/>
                    <measurement group_id="O8" value="2.49" lower_limit="1.52" upper_limit="4.09"/>
                    <measurement group_id="O9" value="5.48" lower_limit="2.18" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 365, N=21,22,16,20,10,20,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="11" upper_limit="59"/>
                    <measurement group_id="O2" value="2.62" lower_limit="1.39" upper_limit="4.94"/>
                    <measurement group_id="O3" value="44" lower_limit="18" upper_limit="105"/>
                    <measurement group_id="O4" value="3.03" lower_limit="1.30" upper_limit="7.06"/>
                    <measurement group_id="O5" value="54" lower_limit="17" upper_limit="174"/>
                    <measurement group_id="O6" value="53" lower_limit="22" upper_limit="130"/>
                    <measurement group_id="O7" value="34" lower_limit="16" upper_limit="69"/>
                    <measurement group_id="O8" value="6.52" lower_limit="2.71" upper_limit="16"/>
                    <measurement group_id="O9" value="3.54" lower_limit="1.40" upper_limit="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1, N=20,19,14,20,11,19,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="8.21" upper_limit="39"/>
                    <measurement group_id="O2" value="19" lower_limit="7.54" upper_limit="49"/>
                    <measurement group_id="O3" value="19" lower_limit="8.13" upper_limit="44"/>
                    <measurement group_id="O4" value="10" lower_limit="5.52" upper_limit="19"/>
                    <measurement group_id="O5" value="5.20" lower_limit="2.80" upper_limit="9.65"/>
                    <measurement group_id="O6" value="7.83" lower_limit="4.51" upper_limit="14"/>
                    <measurement group_id="O7" value="7.89" lower_limit="4.26" upper_limit="15"/>
                    <measurement group_id="O8" value="8.45" lower_limit="2.64" upper_limit="27"/>
                    <measurement group_id="O9" value="24" lower_limit="9.34" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 365, N=21,21,16,20,11,19,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="75" upper_limit="217"/>
                    <measurement group_id="O2" value="15" lower_limit="5.82" upper_limit="39"/>
                    <measurement group_id="O3" value="177" lower_limit="102" upper_limit="305"/>
                    <measurement group_id="O4" value="9.14" lower_limit="4.07" upper_limit="21"/>
                    <measurement group_id="O5" value="29" lower_limit="10" upper_limit="82"/>
                    <measurement group_id="O6" value="32" lower_limit="16" upper_limit="67"/>
                    <measurement group_id="O7" value="81" lower_limit="46" upper_limit="141"/>
                    <measurement group_id="O8" value="72" lower_limit="27" upper_limit="191"/>
                    <measurement group_id="O9" value="24" lower_limit="8.98" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 1, N=20,22,12,20,11,20,17,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="21" upper_limit="62"/>
                    <measurement group_id="O2" value="43" lower_limit="24" upper_limit="79"/>
                    <measurement group_id="O3" value="30" lower_limit="7.82" upper_limit="112"/>
                    <measurement group_id="O4" value="17" lower_limit="6.88" upper_limit="43"/>
                    <measurement group_id="O5" value="25" lower_limit="7.98" upper_limit="79"/>
                    <measurement group_id="O6" value="23" lower_limit="9.81" upper_limit="52"/>
                    <measurement group_id="O7" value="28" lower_limit="11" upper_limit="70"/>
                    <measurement group_id="O8" value="15" lower_limit="4.54" upper_limit="47"/>
                    <measurement group_id="O9" value="10" lower_limit="3.53" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 365, N=21,22,16,20,11,20,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="133" upper_limit="272"/>
                    <measurement group_id="O2" value="28" lower_limit="13" upper_limit="59"/>
                    <measurement group_id="O3" value="213" lower_limit="135" upper_limit="337"/>
                    <measurement group_id="O4" value="16" lower_limit="5.58" upper_limit="47"/>
                    <measurement group_id="O5" value="80" lower_limit="26" upper_limit="246"/>
                    <measurement group_id="O6" value="96" lower_limit="72" upper_limit="127"/>
                    <measurement group_id="O7" value="172" lower_limit="97" upper_limit="306"/>
                    <measurement group_id="O8" value="104" lower_limit="49" upper_limit="221"/>
                    <measurement group_id="O9" value="16" lower_limit="5.27" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1, N=21,21,14,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4.39" upper_limit="24"/>
                    <measurement group_id="O2" value="16" lower_limit="4.85" upper_limit="54"/>
                    <measurement group_id="O3" value="24" lower_limit="6.62" upper_limit="90"/>
                    <measurement group_id="O4" value="5.39" lower_limit="2.06" upper_limit="14"/>
                    <measurement group_id="O5" value="2.40" lower_limit="1.05" upper_limit="5.47"/>
                    <measurement group_id="O6" value="1.90" lower_limit="1.02" upper_limit="3.55"/>
                    <measurement group_id="O7" value="7.05" lower_limit="3.08" upper_limit="16"/>
                    <measurement group_id="O8" value="6.83" lower_limit="2.11" upper_limit="22"/>
                    <measurement group_id="O9" value="7.03" lower_limit="1.99" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 365, N=21,21,16,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="58" upper_limit="231"/>
                    <measurement group_id="O2" value="18" lower_limit="5.05" upper_limit="62"/>
                    <measurement group_id="O3" value="235" lower_limit="147" upper_limit="376"/>
                    <measurement group_id="O4" value="5.93" lower_limit="1.97" upper_limit="18"/>
                    <measurement group_id="O5" value="7.17" lower_limit="1.91" upper_limit="27"/>
                    <measurement group_id="O6" value="20" lower_limit="6.92" upper_limit="58"/>
                    <measurement group_id="O7" value="193" lower_limit="123" upper_limit="301"/>
                    <measurement group_id="O8" value="101" lower_limit="36" upper_limit="280"/>
                    <measurement group_id="O9" value="9.56" lower_limit="2.44" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>17. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.</title>
        <description>The HT-hSBA GMTs against N. meningitidis strains of serogroups B, at 24 and 36 months after the primary vaccination.</description>
        <time_frame>Day 1 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>17. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.</title>
          <description>The HT-hSBA GMTs against N. meningitidis strains of serogroups B, at 24 and 36 months after the primary vaccination.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster) population. All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N= 21,22,14,20,9,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="9.47" upper_limit="34"/>
                    <measurement group_id="O2" value="18" lower_limit="9.50" upper_limit="34"/>
                    <measurement group_id="O3" value="31" lower_limit="12" upper_limit="85"/>
                    <measurement group_id="O4" value="31" lower_limit="15" upper_limit="65"/>
                    <measurement group_id="O5" value="27" lower_limit="8.61" upper_limit="86"/>
                    <measurement group_id="O6" value="39" lower_limit="21" upper_limit="74"/>
                    <measurement group_id="O7" value="2.97" lower_limit="1.58" upper_limit="5.59"/>
                    <measurement group_id="O8" value="1.80" lower_limit="1.01" upper_limit="3.22"/>
                    <measurement group_id="O9" value="3.20" lower_limit="1.44" upper_limit="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 365, N= 21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" lower_limit="79" upper_limit="385"/>
                    <measurement group_id="O2" value="13" lower_limit="6.07" upper_limit="29"/>
                    <measurement group_id="O3" value="305" lower_limit="149" upper_limit="625"/>
                    <measurement group_id="O4" value="23" lower_limit="11" upper_limit="47"/>
                    <measurement group_id="O5" value="587" lower_limit="351" upper_limit="983"/>
                    <measurement group_id="O6" value="491" lower_limit="258" upper_limit="936"/>
                    <measurement group_id="O7" value="6.05" lower_limit="3.10" upper_limit="12"/>
                    <measurement group_id="O8" value="4.23" lower_limit="1.48" upper_limit="12"/>
                    <measurement group_id="O9" value="2.45" lower_limit="1" upper_limit="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N= 21,22,15,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="1.66" upper_limit="7.71"/>
                    <measurement group_id="O2" value="2.23" lower_limit="1.28" upper_limit="3.90"/>
                    <measurement group_id="O3" value="1.49" lower_limit="0.96" upper_limit="2.33"/>
                    <measurement group_id="O4" value="1.73" lower_limit="0.97" upper_limit="3.10"/>
                    <measurement group_id="O5" value="3.45" lower_limit="1.81" upper_limit="6.57"/>
                    <measurement group_id="O6" value="3.43" lower_limit="1.83" upper_limit="6.43"/>
                    <measurement group_id="O7" value="1.34" lower_limit="0.85" upper_limit="2.13"/>
                    <measurement group_id="O8" value="1.51" lower_limit="0.91" upper_limit="2.48"/>
                    <measurement group_id="O9" value="1.19" lower_limit="0.97" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 365, N= 21,22,16,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="5.18" upper_limit="26"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.20" upper_limit="3.10"/>
                    <measurement group_id="O3" value="4.19" lower_limit="1.93" upper_limit="9.11"/>
                    <measurement group_id="O4" value="1.83" lower_limit="1.07" upper_limit="3.15"/>
                    <measurement group_id="O5" value="21" lower_limit="6.00" upper_limit="71"/>
                    <measurement group_id="O6" value="11" lower_limit="4.68" upper_limit="25"/>
                    <measurement group_id="O7" value="1.96" lower_limit="1.21" upper_limit="3.19"/>
                    <measurement group_id="O8" value="1.92" lower_limit="1.17" upper_limit="3.17"/>
                    <measurement group_id="O9" value="1.49" lower_limit="0.90" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N= 21,22,14,18,10,19,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.25" upper_limit="4.36"/>
                    <measurement group_id="O2" value="3.39" lower_limit="1.43" upper_limit="8.05"/>
                    <measurement group_id="O3" value="2.87" lower_limit="0.86" upper_limit="9.59"/>
                    <measurement group_id="O4" value="1.26" lower_limit="0.89" upper_limit="1.80"/>
                    <measurement group_id="O5" value="2.46" lower_limit="0.72" upper_limit="8.40"/>
                    <measurement group_id="O6" value="6.29" lower_limit="2.22" upper_limit="18"/>
                    <measurement group_id="O7" value="1.24" lower_limit="0.79" upper_limit="1.94"/>
                    <measurement group_id="O8" value="1.24" lower_limit="0.88" upper_limit="1.77"/>
                    <measurement group_id="O9" value="1.68" lower_limit="0.85" upper_limit="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364(Day 365,N= 21,22,16,18,11,19,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="9.54" upper_limit="93"/>
                    <measurement group_id="O2" value="3.55" lower_limit="1.56" upper_limit="8.07"/>
                    <measurement group_id="O3" value="74" lower_limit="18" upper_limit="300"/>
                    <measurement group_id="O4" value="1.23" lower_limit="0.91" upper_limit="1.68"/>
                    <measurement group_id="O5" value="303" lower_limit="174" upper_limit="527"/>
                    <measurement group_id="O6" value="155" lower_limit="69" upper_limit="350"/>
                    <measurement group_id="O7" value="1.61" lower_limit="0.99" upper_limit="2.63"/>
                    <measurement group_id="O8" value="1.71" lower_limit="0.86" upper_limit="3.42"/>
                    <measurement group_id="O9" value="2.03" lower_limit="0.90" upper_limit="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1, N= 21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="2.07" upper_limit="6.54"/>
                    <measurement group_id="O2" value="4.20" lower_limit="2.25" upper_limit="7.85"/>
                    <measurement group_id="O3" value="2.28" lower_limit="1.16" upper_limit="4.48"/>
                    <measurement group_id="O4" value="2.36" lower_limit="1.51" upper_limit="3.70"/>
                    <measurement group_id="O5" value="4.10" lower_limit="1.89" upper_limit="8.90"/>
                    <measurement group_id="O6" value="7.35" lower_limit="3.82" upper_limit="14"/>
                    <measurement group_id="O7" value="2.08" lower_limit="1.26" upper_limit="3.42"/>
                    <measurement group_id="O8" value="2.15" lower_limit="1.14" upper_limit="4.05"/>
                    <measurement group_id="O9" value="3.50" lower_limit="1.57" upper_limit="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 365,N=21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" lower_limit="4.60" upper_limit="14"/>
                    <measurement group_id="O2" value="3.28" lower_limit="2.16" upper_limit="4.97"/>
                    <measurement group_id="O3" value="4.09" lower_limit="2.30" upper_limit="7.25"/>
                    <measurement group_id="O4" value="2.04" lower_limit="1.43" upper_limit="2.92"/>
                    <measurement group_id="O5" value="10" lower_limit="4.51" upper_limit="24"/>
                    <measurement group_id="O6" value="11" lower_limit="6.35" upper_limit="18"/>
                    <measurement group_id="O7" value="2.45" lower_limit="1.59" upper_limit="3.79"/>
                    <measurement group_id="O8" value="1.91" lower_limit="1.14" upper_limit="3.23"/>
                    <measurement group_id="O9" value="3.92" lower_limit="1.90" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N= 21,22,14,20,11,20,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" lower_limit="1.51" upper_limit="4.78"/>
                    <measurement group_id="O2" value="2.94" lower_limit="1.77" upper_limit="4.89"/>
                    <measurement group_id="O3" value="1.54" lower_limit="0.90" upper_limit="2.63"/>
                    <measurement group_id="O4" value="2.01" lower_limit="1.40" upper_limit="2.88"/>
                    <measurement group_id="O5" value="3.11" lower_limit="1.74" upper_limit="5.56"/>
                    <measurement group_id="O6" value="3.37" lower_limit="1.95" upper_limit="5.81"/>
                    <measurement group_id="O7" value="1.85" lower_limit="1.13" upper_limit="3.04"/>
                    <measurement group_id="O8" value="1.48" lower_limit="1.03" upper_limit="2.13"/>
                    <measurement group_id="O9" value="2.55" lower_limit="1.37" upper_limit="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 365, N= 21,22,16,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.19" lower_limit="3.89" upper_limit="13"/>
                    <measurement group_id="O2" value="1.67" lower_limit="1.07" upper_limit="2.60"/>
                    <measurement group_id="O3" value="2.94" lower_limit="1.49" upper_limit="5.80"/>
                    <measurement group_id="O4" value="1.47" lower_limit="1.07" upper_limit="2.03"/>
                    <measurement group_id="O5" value="11" lower_limit="4.41" upper_limit="28"/>
                    <measurement group_id="O6" value="7.12" lower_limit="3.59" upper_limit="14"/>
                    <measurement group_id="O7" value="2.09" lower_limit="1.33" upper_limit="3.29"/>
                    <measurement group_id="O8" value="1.38" lower_limit="0.98" upper_limit="1.93"/>
                    <measurement group_id="O9" value="2.17" lower_limit="1.07" upper_limit="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N= 21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.06" upper_limit="2.81"/>
                    <measurement group_id="O2" value="2.34" lower_limit="1.33" upper_limit="4.10"/>
                    <measurement group_id="O3" value="1.34" lower_limit="0.94" upper_limit="1.93"/>
                    <measurement group_id="O4" value="1.48" lower_limit="1.01" upper_limit="2.17"/>
                    <measurement group_id="O5" value="1.72" lower_limit="0.99" upper_limit="2.98"/>
                    <measurement group_id="O6" value="2.24" lower_limit="1.20" upper_limit="4.17"/>
                    <measurement group_id="O7" value="1.18" lower_limit="0.84" upper_limit="1.66"/>
                    <measurement group_id="O8" value="1.19" lower_limit="0.90" upper_limit="1.58"/>
                    <measurement group_id="O9" value="1.13" lower_limit="0.94" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 365, N= 21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" lower_limit="2.12" upper_limit="5.74"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.41" upper_limit="2.57"/>
                    <measurement group_id="O3" value="2.67" lower_limit="1.27" upper_limit="5.61"/>
                    <measurement group_id="O4" value="1.23" lower_limit="0.90" upper_limit="1.69"/>
                    <measurement group_id="O5" value="3.28" lower_limit="1.66" upper_limit="6.49"/>
                    <measurement group_id="O6" value="3.77" lower_limit="1.98" upper_limit="7.18"/>
                    <measurement group_id="O7" value="1.65" lower_limit="1.04" upper_limit="2.61"/>
                    <measurement group_id="O8" value="1.19" lower_limit="0.91" upper_limit="1.54"/>
                    <measurement group_id="O9" value="1.28" lower_limit="0.85" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>18. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 against N. meningitidis serogroups A, C, W, Y at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
        <time_frame>Day 1, Day 30 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>18. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 against N. meningitidis serogroups A, C, W, Y at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1,N=21,22,15,20,10,20,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="18" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O4" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O5" value="30" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O6" value="35" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O7" value="45" lower_limit="23.1" upper_limit="68.5"/>
                    <measurement group_id="O8" value="12" lower_limit="1.5" upper_limit="36.4"/>
                    <measurement group_id="O9" value="41" lower_limit="18.4" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 30, N=21,22,15,19,10,20,18,16,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="32" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="26" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O5" value="100" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O7" value="100" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O9" value="44" lower_limit="19.8" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 365, N=21,22,16,20,10,20,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O2" value="23" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="88" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O4" value="25" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O5" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O6" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O7" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O8" value="50" lower_limit="26.0" upper_limit="74.0"/>
                    <measurement group_id="O9" value="35" lower_limit="14.2" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1, N=20,19,14,20,11,19,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O2" value="68" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O3" value="71" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O7" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O8" value="50" lower_limit="26.0" upper_limit="74.0"/>
                    <measurement group_id="O9" value="75" lower_limit="47.6" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 30, N=17,20,10,20,7,14,19,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O3" value="100" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="55" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O5" value="100" lower_limit="59.0" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100" lower_limit="76.8" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O8" value="88" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O9" value="69" lower_limit="41.3" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 365, N=21,21,16,20,11,19,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="50" lower_limit="27.2" upper_limit="72.8"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="95" lower_limit="74.0" upper_limit="99.87"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="65" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 1,N=20,22,12,20,11,20,17,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O2" value="95" lower_limit="77.2" upper_limit="99.88"/>
                    <measurement group_id="O3" value="75" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O4" value="70" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O7" value="82" lower_limit="56.6" upper_limit="96.2"/>
                    <measurement group_id="O8" value="61" lower_limit="35.7" upper_limit="82.7"/>
                    <measurement group_id="O9" value="56" lower_limit="29.9" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 30, N=18,22,15,19,11,18,17,16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="86" lower_limit="65.1" upper_limit="97.1"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="74" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O9" value="57" lower_limit="28.9" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 365, N=21,22,16,20,11,20,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="82" lower_limit="59.7" upper_limit="94.8"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O8" value="100" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O9" value="65" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1, N=21,21,14,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O2" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O3" value="71" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="11" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O7" value="55" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O8" value="44" lower_limit="21.5" upper_limit="69.2"/>
                    <measurement group_id="O9" value="41" lower_limit="18.4" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 30, N=21,21,15,20,11,18,20,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="57" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="83" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O7" value="100" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O8" value="100" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O9" value="38" lower_limit="15.2" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 365, N=21,21,16,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="52" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="72" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O7" value="100" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="47" lower_limit="23.0" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>19. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitides strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
        <time_frame>Day 1, Day 30 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O3">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O4">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O5">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>19. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:5 against N. meningitides strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1,N= 21,14,9,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O2" value="86" lower_limit="57.2" upper_limit="98.2"/>
                    <measurement group_id="O3" value="89" lower_limit="51.8" upper_limit="99.72"/>
                    <measurement group_id="O4" value="95" lower_limit="74" upper_limit="99.87"/>
                    <measurement group_id="O5" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O6" value="17" lower_limit="3.6" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N= 21,16,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O5" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O6" value="83" lower_limit="58.6" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 365, 21,16,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O5" value="43" lower_limit="21.8" upper_limit="66"/>
                    <measurement group_id="O6" value="33" lower_limit="13.3" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N= 21,15,11,20,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O2" value="13" lower_limit="1.7" upper_limit="40.5"/>
                    <measurement group_id="O3" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O4" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O5" value="5" lower_limit="0.12" upper_limit="23.8"/>
                    <measurement group_id="O6" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, N= 21,16,11,20,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O5" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O6" value="33" lower_limit="13.3" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 365, N= 21,16,11,20,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O2" value="44" lower_limit="19.8" upper_limit="70.1"/>
                    <measurement group_id="O3" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O4" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O5" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O6" value="11" lower_limit="1.4" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N= 21,14,10,19,20,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O2" value="21" lower_limit="4.7" upper_limit="50.8"/>
                    <measurement group_id="O3" value="20" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O4" value="42" lower_limit="20.3" upper_limit="66.5"/>
                    <measurement group_id="O5" value="5" lower_limit="0.13" upper_limit="24.9"/>
                    <measurement group_id="O6" value="6" lower_limit="0.15" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364(Day 30, N= 21,16,11,19,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O5" value="21" lower_limit="6.1" upper_limit="45.6"/>
                    <measurement group_id="O6" value="28" lower_limit="9.7" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 365, N= 21,16,11,19,20,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O2" value="75" lower_limit="47.6" upper_limit="92.7"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="95" lower_limit="74" upper_limit="99.87"/>
                    <measurement group_id="O5" value="15" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O6" value="11" lower_limit="1.4" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1, N= 21,14,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="29" lower_limit="8.4" upper_limit="58.1"/>
                    <measurement group_id="O3" value="64" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O4" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O5" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O6" value="17" lower_limit="3.6" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30, N= 21,16,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O3" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O4" value="95" lower_limit="74" upper_limit="99.87"/>
                    <measurement group_id="O5" value="33" lower_limit="14.6" upper_limit="57"/>
                    <measurement group_id="O6" value="22" lower_limit="6.4" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084(Day 365, N=21,16,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O2" value="50" lower_limit="24.7" upper_limit="75.3"/>
                    <measurement group_id="O3" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O4" value="74" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O5" value="29" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O6" value="17" lower_limit="3.6" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N= 21,14,11,20,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O2" value="7" lower_limit="0.18" upper_limit="33.9"/>
                    <measurement group_id="O3" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O4" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O5" value="10" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O6" value="11" lower_limit="1.4" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N= 21,16,11,20,20,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="88" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O5" value="35" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O6" value="33" lower_limit="13.3" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 365, N= 21,16,11,20,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="34" upper_limit="78.2"/>
                    <measurement group_id="O2" value="38" lower_limit="15.2" upper_limit="64.6"/>
                    <measurement group_id="O3" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O4" value="60" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O5" value="14" lower_limit="3" upper_limit="36.3"/>
                    <measurement group_id="O6" value="11" lower_limit="1.4" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1,N= 21,14,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O2" value="7" lower_limit="0.18" upper_limit="33.9"/>
                    <measurement group_id="O3" value="9" lower_limit="0.23" upper_limit="41.3"/>
                    <measurement group_id="O4" value="26" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O5" value="5" lower_limit="0.12" upper_limit="23.8"/>
                    <measurement group_id="O6" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N= 21,16,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="75" lower_limit="47.6" upper_limit="92.7"/>
                    <measurement group_id="O3" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O4" value="95" lower_limit="74" upper_limit="99.87"/>
                    <measurement group_id="O5" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O6" value="17" lower_limit="3.6" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 365, N= 21,16,11,19,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O2" value="31" lower_limit="11" upper_limit="58.7"/>
                    <measurement group_id="O3" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O4" value="42" lower_limit="20.3" upper_limit="66.5"/>
                    <measurement group_id="O5" value="19" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O6" value="6" lower_limit="0.14" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>20. The HT-hSBA GMTs Against Neisseria Meningitidis Serogroups A, C, W,Y and Strains of Serogroups B.</title>
        <description>The HT-hSBA GMTs against Neisseria meningitidis serogroup A, C, W, Y and strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
        <time_frame>Day 1, Day 30 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>20. The HT-hSBA GMTs Against Neisseria Meningitidis Serogroups A, C, W,Y and Strains of Serogroups B.</title>
          <description>The HT-hSBA GMTs against Neisseria meningitidis serogroup A, C, W, Y and strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1, N= 21,22,15,20,10,20,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="1.98" upper_limit="8"/>
                    <measurement group_id="O2" value="2.73" lower_limit="1.44" upper_limit="5.15"/>
                    <measurement group_id="O3" value="3.07" lower_limit="1.26" upper_limit="7.47"/>
                    <measurement group_id="O4" value="2.98" lower_limit="1.38" upper_limit="6.42"/>
                    <measurement group_id="O5" value="2.27" lower_limit="0.87" upper_limit="5.94"/>
                    <measurement group_id="O6" value="4.22" lower_limit="1.63" upper_limit="11"/>
                    <measurement group_id="O7" value="6.31" lower_limit="2.82" upper_limit="14"/>
                    <measurement group_id="O8" value="2.49" lower_limit="1.52" upper_limit="4.09"/>
                    <measurement group_id="O9" value="5.48" lower_limit="2.18" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 30, N= 21,22,15,19,10,20,18,16,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275" lower_limit="174" upper_limit="435"/>
                    <measurement group_id="O2" value="3.88" lower_limit="1.74" upper_limit="8.66"/>
                    <measurement group_id="O3" value="348" lower_limit="202" upper_limit="601"/>
                    <measurement group_id="O4" value="2.95" lower_limit="1.41" upper_limit="6.17"/>
                    <measurement group_id="O5" value="445" lower_limit="277" upper_limit="715"/>
                    <measurement group_id="O6" value="428" lower_limit="196" upper_limit="931"/>
                    <measurement group_id="O7" value="140" lower_limit="82" upper_limit="239"/>
                    <measurement group_id="O8" value="46" lower_limit="23" upper_limit="91"/>
                    <measurement group_id="O9" value="5.99" lower_limit="2.27" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 365, N= 21,22,16,20,10,20,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="11" upper_limit="59"/>
                    <measurement group_id="O2" value="2.62" lower_limit="1.39" upper_limit="4.94"/>
                    <measurement group_id="O3" value="44" lower_limit="18" upper_limit="105"/>
                    <measurement group_id="O4" value="3.03" lower_limit="1.30" upper_limit="7.06"/>
                    <measurement group_id="O5" value="54" lower_limit="17" upper_limit="174"/>
                    <measurement group_id="O6" value="53" lower_limit="22" upper_limit="130"/>
                    <measurement group_id="O7" value="34" lower_limit="16" upper_limit="69"/>
                    <measurement group_id="O8" value="6.52" lower_limit="2.71" upper_limit="16"/>
                    <measurement group_id="O9" value="3.54" lower_limit="1.40" upper_limit="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1, N= 20,19,14,20,11,19,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="8.21" upper_limit="39"/>
                    <measurement group_id="O2" value="19" lower_limit="7.54" upper_limit="49"/>
                    <measurement group_id="O3" value="19" lower_limit="8.13" upper_limit="44"/>
                    <measurement group_id="O4" value="10" lower_limit="5.52" upper_limit="19"/>
                    <measurement group_id="O5" value="5.20" lower_limit="2.80" upper_limit="9.65"/>
                    <measurement group_id="O6" value="7.83" lower_limit="4.51" upper_limit="14"/>
                    <measurement group_id="O7" value="7.89" lower_limit="4.26" upper_limit="15"/>
                    <measurement group_id="O8" value="8.45" lower_limit="2.64" upper_limit="27"/>
                    <measurement group_id="O9" value="24" lower_limit="9.34" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 30, N= 17,20,10,20,7,14,19,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="737" lower_limit="459" upper_limit="1183"/>
                    <measurement group_id="O2" value="21" lower_limit="8.38" upper_limit="52"/>
                    <measurement group_id="O3" value="766" lower_limit="325" upper_limit="1804"/>
                    <measurement group_id="O4" value="8.43" lower_limit="4.37" upper_limit="16"/>
                    <measurement group_id="O5" value="292" lower_limit="75" upper_limit="1142"/>
                    <measurement group_id="O6" value="102" lower_limit="57" upper_limit="181"/>
                    <measurement group_id="O7" value="322" lower_limit="186" upper_limit="556"/>
                    <measurement group_id="O8" value="307" lower_limit="118" upper_limit="795"/>
                    <measurement group_id="O9" value="27" lower_limit="9.15" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 365, N= 21,21,16,20,11,19,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="75" upper_limit="217"/>
                    <measurement group_id="O2" value="15" lower_limit="5.82" upper_limit="39"/>
                    <measurement group_id="O3" value="177" lower_limit="102" upper_limit="305"/>
                    <measurement group_id="O4" value="9.14" lower_limit="4.07" upper_limit="21"/>
                    <measurement group_id="O5" value="29" lower_limit="10" upper_limit="82"/>
                    <measurement group_id="O6" value="32" lower_limit="16" upper_limit="67"/>
                    <measurement group_id="O7" value="81" lower_limit="46" upper_limit="141"/>
                    <measurement group_id="O8" value="72" lower_limit="27" upper_limit="191"/>
                    <measurement group_id="O9" value="24" lower_limit="8.98" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 1, N= 20,22,12,20,11,20,17,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="21" upper_limit="62"/>
                    <measurement group_id="O2" value="43" lower_limit="24" upper_limit="79"/>
                    <measurement group_id="O3" value="30" lower_limit="7.82" upper_limit="112"/>
                    <measurement group_id="O4" value="17" lower_limit="6.88" upper_limit="43"/>
                    <measurement group_id="O5" value="25" lower_limit="7.98" upper_limit="79"/>
                    <measurement group_id="O6" value="23" lower_limit="9.81" upper_limit="52"/>
                    <measurement group_id="O7" value="28" lower_limit="11" upper_limit="70"/>
                    <measurement group_id="O8" value="15" lower_limit="4.54" upper_limit="47"/>
                    <measurement group_id="O9" value="10" lower_limit="3.53" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 30, N= 18,22,15,19,11,18,17,16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="844" lower_limit="535" upper_limit="1333"/>
                    <measurement group_id="O2" value="46" lower_limit="23" upper_limit="89"/>
                    <measurement group_id="O3" value="890" lower_limit="665" upper_limit="1190"/>
                    <measurement group_id="O4" value="22" lower_limit="8.89" upper_limit="52"/>
                    <measurement group_id="O5" value="392" lower_limit="252" upper_limit="610"/>
                    <measurement group_id="O6" value="395" lower_limit="321" upper_limit="487"/>
                    <measurement group_id="O7" value="620" lower_limit="354" upper_limit="1085"/>
                    <measurement group_id="O8" value="360" lower_limit="169" upper_limit="765"/>
                    <measurement group_id="O9" value="13" lower_limit="3.50" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 365, N= 21,22,16,20,11,20,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="133" upper_limit="272"/>
                    <measurement group_id="O2" value="28" lower_limit="13" upper_limit="59"/>
                    <measurement group_id="O3" value="213" lower_limit="135" upper_limit="337"/>
                    <measurement group_id="O4" value="16" lower_limit="5.58" upper_limit="47"/>
                    <measurement group_id="O5" value="80" lower_limit="26" upper_limit="246"/>
                    <measurement group_id="O6" value="96" lower_limit="72" upper_limit="127"/>
                    <measurement group_id="O7" value="172" lower_limit="97" upper_limit="306"/>
                    <measurement group_id="O8" value="104" lower_limit="49" upper_limit="221"/>
                    <measurement group_id="O9" value="16" lower_limit="5.27" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1, N= 21,21,14,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4.39" upper_limit="24"/>
                    <measurement group_id="O2" value="16" lower_limit="4.85" upper_limit="54"/>
                    <measurement group_id="O3" value="24" lower_limit="6.62" upper_limit="90"/>
                    <measurement group_id="O4" value="5.39" lower_limit="2.06" upper_limit="14"/>
                    <measurement group_id="O5" value="2.40" lower_limit="1.05" upper_limit="5.47"/>
                    <measurement group_id="O6" value="1.90" lower_limit="1.02" upper_limit="3.55"/>
                    <measurement group_id="O7" value="7.05" lower_limit="3.08" upper_limit="16"/>
                    <measurement group_id="O8" value="6.83" lower_limit="2.11" upper_limit="22"/>
                    <measurement group_id="O9" value="7.03" lower_limit="1.99" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 30, N= 21,21,15,20,11,18,20,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444" lower_limit="257" upper_limit="768"/>
                    <measurement group_id="O2" value="17" lower_limit="4.77" upper_limit="57"/>
                    <measurement group_id="O3" value="748" lower_limit="463" upper_limit="1208"/>
                    <measurement group_id="O4" value="4.86" lower_limit="1.86" upper_limit="13"/>
                    <measurement group_id="O5" value="48" lower_limit="14" upper_limit="157"/>
                    <measurement group_id="O6" value="54" lower_limit="17" upper_limit="171"/>
                    <measurement group_id="O7" value="662" lower_limit="424" upper_limit="1032"/>
                    <measurement group_id="O8" value="404" lower_limit="201" upper_limit="811"/>
                    <measurement group_id="O9" value="6.84" lower_limit="1.78" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 365, N= 21,21,16,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="58" upper_limit="231"/>
                    <measurement group_id="O2" value="18" lower_limit="5.05" upper_limit="62"/>
                    <measurement group_id="O3" value="235" lower_limit="147" upper_limit="376"/>
                    <measurement group_id="O4" value="5.93" lower_limit="1.97" upper_limit="18"/>
                    <measurement group_id="O5" value="7.17" lower_limit="1.91" upper_limit="27"/>
                    <measurement group_id="O6" value="20" lower_limit="6.92" upper_limit="58"/>
                    <measurement group_id="O7" value="193" lower_limit="123" upper_limit="301"/>
                    <measurement group_id="O8" value="101" lower_limit="36" upper_limit="280"/>
                    <measurement group_id="O9" value="9.56" lower_limit="2.44" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>21. The HT-hSBA GMTs Against Neisseria Meningitidis Strains of Serogroups B.</title>
        <description>The HT-hSBA GMTs against Neisseria meningitidis strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
        <time_frame>Day 1, Day 30 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>21. The HT-hSBA GMTs Against Neisseria Meningitidis Strains of Serogroups B.</title>
          <description>The HT-hSBA GMTs against Neisseria meningitidis strains of serogroups B at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 (Day 1, N=21,22,14,20,9,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="9.47" upper_limit="34"/>
                    <measurement group_id="O2" value="18" lower_limit="9.50" upper_limit="34"/>
                    <measurement group_id="O3" value="31" lower_limit="12" upper_limit="85"/>
                    <measurement group_id="O4" value="31" lower_limit="15" upper_limit="65"/>
                    <measurement group_id="O5" value="27" lower_limit="8.61" upper_limit="86"/>
                    <measurement group_id="O6" value="39" lower_limit="21" upper_limit="74"/>
                    <measurement group_id="O7" value="2.97" lower_limit="1.58" upper_limit="5.59"/>
                    <measurement group_id="O8" value="1.8" lower_limit="1.01" upper_limit="3.22"/>
                    <measurement group_id="O9" value="3.2" lower_limit="1.44" upper_limit="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 30, N=21,22,16,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1147" lower_limit="665" upper_limit="1980"/>
                    <measurement group_id="O2" value="23" lower_limit="11" upper_limit="48"/>
                    <measurement group_id="O3" value="1598" lower_limit="864" upper_limit="2956"/>
                    <measurement group_id="O4" value="35" lower_limit="19" upper_limit="65"/>
                    <measurement group_id="O5" value="2205" lower_limit="1560" upper_limit="3117"/>
                    <measurement group_id="O6" value="2816" lower_limit="1856" upper_limit="4273"/>
                    <measurement group_id="O7" value="28" lower_limit="11" upper_limit="67"/>
                    <measurement group_id="O8" value="29" lower_limit="10" upper_limit="80"/>
                    <measurement group_id="O9" value="3.98" lower_limit="1.24" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 365, N=21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" lower_limit="79" upper_limit="385"/>
                    <measurement group_id="O2" value="13" lower_limit="6.07" upper_limit="29"/>
                    <measurement group_id="O3" value="305" lower_limit="149" upper_limit="625"/>
                    <measurement group_id="O4" value="23" lower_limit="11" upper_limit="47"/>
                    <measurement group_id="O5" value="587" lower_limit="351" upper_limit="983"/>
                    <measurement group_id="O6" value="491" lower_limit="258" upper_limit="936"/>
                    <measurement group_id="O7" value="6.05" lower_limit="3.10" upper_limit="12"/>
                    <measurement group_id="O8" value="4.23" lower_limit="1.48" upper_limit="12"/>
                    <measurement group_id="O9" value="2.45" lower_limit="1" upper_limit="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 1, N=21,22,15,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="1.66" upper_limit="7.71"/>
                    <measurement group_id="O2" value="2.23" lower_limit="1.28" upper_limit="3.90"/>
                    <measurement group_id="O3" value="1.49" lower_limit="0.96" upper_limit="2.33"/>
                    <measurement group_id="O4" value="1.73" lower_limit="0.97" upper_limit="3.10"/>
                    <measurement group_id="O5" value="3.45" lower_limit="1.81" upper_limit="6.57"/>
                    <measurement group_id="O6" value="3.43" lower_limit="1.83" upper_limit="6.43"/>
                    <measurement group_id="O7" value="1.34" lower_limit="0.85" upper_limit="2.13"/>
                    <measurement group_id="O8" value="1.51" lower_limit="0.91" upper_limit="2.48"/>
                    <measurement group_id="O9" value="1.19" lower_limit="0.97" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 30, N=21,22,16,20,11,20,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="59" upper_limit="184"/>
                    <measurement group_id="O2" value="2.65" lower_limit="1.48" upper_limit="4.78"/>
                    <measurement group_id="O3" value="57" lower_limit="32" upper_limit="102"/>
                    <measurement group_id="O4" value="2.03" lower_limit="1.11" upper_limit="3.73"/>
                    <measurement group_id="O5" value="132" lower_limit="64" upper_limit="271"/>
                    <measurement group_id="O6" value="79" lower_limit="40" upper_limit="153"/>
                    <measurement group_id="O7" value="5.27" lower_limit="2.54" upper_limit="11"/>
                    <measurement group_id="O8" value="3.89" lower_limit="1.79" upper_limit="8.47"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.67" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 365, N=21,22,16,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="5.18" upper_limit="26"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.20" upper_limit="3.10"/>
                    <measurement group_id="O3" value="4.19" lower_limit="1.93" upper_limit="9.11"/>
                    <measurement group_id="O4" value="1.83" lower_limit="1.07" upper_limit="3.15"/>
                    <measurement group_id="O5" value="21" lower_limit="6" upper_limit="71"/>
                    <measurement group_id="O6" value="11" lower_limit="4.68" upper_limit="25"/>
                    <measurement group_id="O7" value="1.96" lower_limit="1.21" upper_limit="3.19"/>
                    <measurement group_id="O8" value="1.92" lower_limit="1.17" upper_limit="3.17"/>
                    <measurement group_id="O9" value="1.49" lower_limit="0.90" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1, N=21,22,14,18,10,19,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.25" upper_limit="4.36"/>
                    <measurement group_id="O2" value="3.39" lower_limit="1.43" upper_limit="8.05"/>
                    <measurement group_id="O3" value="2.87" lower_limit="0.86" upper_limit="9.59"/>
                    <measurement group_id="O4" value="1.26" lower_limit="0.89" upper_limit="1.80"/>
                    <measurement group_id="O5" value="2.46" lower_limit="0.72" upper_limit="8.40"/>
                    <measurement group_id="O6" value="6.29" lower_limit="2.22" upper_limit="18"/>
                    <measurement group_id="O7" value="1.24" lower_limit="0.79" upper_limit="1.94"/>
                    <measurement group_id="O8" value="1.24" lower_limit="0.88" upper_limit="1.77"/>
                    <measurement group_id="O9" value="1.68" lower_limit="0.85" upper_limit="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 30, N=21,22,16,17,11,19,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679" lower_limit="352" upper_limit="1310"/>
                    <measurement group_id="O2" value="3.57" lower_limit="1.39" upper_limit="9.14"/>
                    <measurement group_id="O3" value="903" lower_limit="463" upper_limit="1761"/>
                    <measurement group_id="O4" value="1.23" lower_limit="0.89" upper_limit="1.70"/>
                    <measurement group_id="O5" value="1336" lower_limit="810" upper_limit="2202"/>
                    <measurement group_id="O6" value="1261" lower_limit="746" upper_limit="2131"/>
                    <measurement group_id="O7" value="2.68" lower_limit="1.15" upper_limit="6.25"/>
                    <measurement group_id="O8" value="3.66" lower_limit="1.21" upper_limit="11"/>
                    <measurement group_id="O9" value="1.89" lower_limit="0.72" upper_limit="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 365,N=21,22,16,18,11,19,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="9.54" upper_limit="93"/>
                    <measurement group_id="O2" value="3.55" lower_limit="1.56" upper_limit="8.07"/>
                    <measurement group_id="O3" value="74" lower_limit="18" upper_limit="300"/>
                    <measurement group_id="O4" value="1.23" lower_limit="0.91" upper_limit="1.68"/>
                    <measurement group_id="O5" value="303" lower_limit="174" upper_limit="527"/>
                    <measurement group_id="O6" value="155" lower_limit="69" upper_limit="350"/>
                    <measurement group_id="O7" value="1.61" lower_limit="0.99" upper_limit="2.63"/>
                    <measurement group_id="O8" value="1.71" lower_limit="0.86" upper_limit="3.42"/>
                    <measurement group_id="O9" value="2.03" lower_limit="0.90" upper_limit="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1, N=21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="2.07" upper_limit="6.54"/>
                    <measurement group_id="O2" value="4.2" lower_limit="2.25" upper_limit="7.85"/>
                    <measurement group_id="O3" value="2.28" lower_limit="1.16" upper_limit="4.48"/>
                    <measurement group_id="O4" value="2.36" lower_limit="1.51" upper_limit="3.70"/>
                    <measurement group_id="O5" value="4.1" lower_limit="1.89" upper_limit="8.90"/>
                    <measurement group_id="O6" value="7.35" lower_limit="3.82" upper_limit="14"/>
                    <measurement group_id="O7" value="2.08" lower_limit="1.26" upper_limit="3.42"/>
                    <measurement group_id="O8" value="2.15" lower_limit="1.14" upper_limit="4.05"/>
                    <measurement group_id="O9" value="3.5" lower_limit="1.57" upper_limit="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 30, N=21,22,16,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="36" upper_limit="98"/>
                    <measurement group_id="O2" value="4.37" lower_limit="2.29" upper_limit="8.31"/>
                    <measurement group_id="O3" value="36" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="O4" value="2.2" lower_limit="1.38" upper_limit="3.49"/>
                    <measurement group_id="O5" value="68" lower_limit="33" upper_limit="142"/>
                    <measurement group_id="O6" value="66" lower_limit="35" upper_limit="124"/>
                    <measurement group_id="O7" value="3.26" lower_limit="1.75" upper_limit="6.06"/>
                    <measurement group_id="O8" value="2.24" lower_limit="1.14" upper_limit="4.38"/>
                    <measurement group_id="O9" value="4.57" lower_limit="1.48" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 365,N=21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" lower_limit="4.60" upper_limit="14"/>
                    <measurement group_id="O2" value="3.28" lower_limit="2.16" upper_limit="4.97"/>
                    <measurement group_id="O3" value="4.09" lower_limit="2.30" upper_limit="7.25"/>
                    <measurement group_id="O4" value="2.04" lower_limit="1.43" upper_limit="2.92"/>
                    <measurement group_id="O5" value="10" lower_limit="4.51" upper_limit="24"/>
                    <measurement group_id="O6" value="11" lower_limit="6.35" upper_limit="18"/>
                    <measurement group_id="O7" value="2.45" lower_limit="1.59" upper_limit="3.79"/>
                    <measurement group_id="O8" value="1.91" lower_limit="1.14" upper_limit="3.23"/>
                    <measurement group_id="O9" value="3.92" lower_limit="1.90" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1, N=21,22,14,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" lower_limit="1.51" upper_limit="4.78"/>
                    <measurement group_id="O2" value="2.94" lower_limit="1.77" upper_limit="4.89"/>
                    <measurement group_id="O3" value="1.54" lower_limit="0.90" upper_limit="2.63"/>
                    <measurement group_id="O4" value="2.01" lower_limit="1.40" upper_limit="2.88"/>
                    <measurement group_id="O5" value="3.11" lower_limit="1.74" upper_limit="5.56"/>
                    <measurement group_id="O6" value="3.37" lower_limit="1.95" upper_limit="5.81"/>
                    <measurement group_id="O7" value="1.85" lower_limit="1.13" upper_limit="3.04"/>
                    <measurement group_id="O8" value="1.48" lower_limit="1.03" upper_limit="2.13"/>
                    <measurement group_id="O9" value="2.55" lower_limit="1.37" upper_limit="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 30, N=21,22,16,20,11,20,20,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="21" upper_limit="70"/>
                    <measurement group_id="O2" value="2.31" lower_limit="1.39" upper_limit="3.82"/>
                    <measurement group_id="O3" value="20" lower_limit="10" upper_limit="39"/>
                    <measurement group_id="O4" value="2.03" lower_limit="1.38" upper_limit="2.98"/>
                    <measurement group_id="O5" value="56" lower_limit="27" upper_limit="117"/>
                    <measurement group_id="O6" value="35" lower_limit="21" upper_limit="60"/>
                    <measurement group_id="O7" value="3.44" lower_limit="2.05" upper_limit="5.75"/>
                    <measurement group_id="O8" value="2.71" lower_limit="1.56" upper_limit="4.70"/>
                    <measurement group_id="O9" value="3.05" lower_limit="1.05" upper_limit="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 365, N=21,22,16,20,11,20,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.19" lower_limit="3.89" upper_limit="13"/>
                    <measurement group_id="O2" value="1.67" lower_limit="1.07" upper_limit="2.60"/>
                    <measurement group_id="O3" value="2.94" lower_limit="1.49" upper_limit="5.80"/>
                    <measurement group_id="O4" value="1.47" lower_limit="1.07" upper_limit="2.03"/>
                    <measurement group_id="O5" value="11" lower_limit="4.41" upper_limit="28"/>
                    <measurement group_id="O6" value="7.12" lower_limit="3.59" upper_limit="14"/>
                    <measurement group_id="O7" value="2.09" lower_limit="1.33" upper_limit="3.29"/>
                    <measurement group_id="O8" value="1.38" lower_limit="0.98" upper_limit="1.93"/>
                    <measurement group_id="O9" value="2.17" lower_limit="1.07" upper_limit="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 1, N=21,22,14,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.06" upper_limit="2.81"/>
                    <measurement group_id="O2" value="2.34" lower_limit="1.33" upper_limit="4.10"/>
                    <measurement group_id="O3" value="1.34" lower_limit="0.94" upper_limit="1.93"/>
                    <measurement group_id="O4" value="1.48" lower_limit="1.01" upper_limit="2.17"/>
                    <measurement group_id="O5" value="1.72" lower_limit="0.99" upper_limit="2.98"/>
                    <measurement group_id="O6" value="2.24" lower_limit="1.20" upper_limit="4.17"/>
                    <measurement group_id="O7" value="1.18" lower_limit="0.84" upper_limit="1.66"/>
                    <measurement group_id="O8" value="1.19" lower_limit="0.90" upper_limit="1.58"/>
                    <measurement group_id="O9" value="1.13" lower_limit="0.94" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 30, N=21,22,16,20,11,19,21,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="19" upper_limit="52"/>
                    <measurement group_id="O2" value="2.23" lower_limit="1.25" upper_limit="3.99"/>
                    <measurement group_id="O3" value="15" lower_limit="5.93" upper_limit="36"/>
                    <measurement group_id="O4" value="1.75" lower_limit="0.98" upper_limit="3.14"/>
                    <measurement group_id="O5" value="17" lower_limit="6.22" upper_limit="45"/>
                    <measurement group_id="O6" value="28" lower_limit="17" upper_limit="47"/>
                    <measurement group_id="O7" value="2.48" lower_limit="1.31" upper_limit="4.69"/>
                    <measurement group_id="O8" value="1.62" lower_limit="0.96" upper_limit="2.74"/>
                    <measurement group_id="O9" value="1.73" lower_limit="0.77" upper_limit="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 365, N=21,22,16,20,11,19,21,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" lower_limit="2.12" upper_limit="5.74"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.14" upper_limit="2.57"/>
                    <measurement group_id="O3" value="2.67" lower_limit="1.27" upper_limit="5.61"/>
                    <measurement group_id="O4" value="1.23" lower_limit="0.90" upper_limit="1.69"/>
                    <measurement group_id="O5" value="3.28" lower_limit="1.66" upper_limit="6.49"/>
                    <measurement group_id="O6" value="3.77" lower_limit="1.98" upper_limit="7.18"/>
                    <measurement group_id="O7" value="1.65" lower_limit="1.04" upper_limit="2.61"/>
                    <measurement group_id="O8" value="1.19" lower_limit="0.91" upper_limit="1.54"/>
                    <measurement group_id="O9" value="1.28" lower_limit="0.85" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>22. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A,C,W,Y at 12 Months After Booster Vaccination.</title>
        <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 to N. meningitidis serogroups A,C,W,Y at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination in this study.</description>
        <time_frame>Day 1, Day 30 and Day 365</time_frame>
        <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>22. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A,C,W,Y at 12 Months After Booster Vaccination.</title>
          <description>Percentage of subjects with HT-hSBA titer ≥ 1:8 to N. meningitidis serogroups A,C,W,Y at Day 1, Day 30 (one month) and Day 365 (12 months) after the administration of MenABCWY booster vaccination in this study.</description>
          <population>Analysis was done on FAS Day 365 (Persistence of Booster). All subjects in the enrolled population who were randomized, actually received the study vaccination in V102_03E1 and provided an evaluable serum sample at Day 365.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1, N= 21,22,15,20,10,20,20,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="18" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O4" value="30" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O5" value="30" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O6" value="35" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O7" value="45" lower_limit="23.1" upper_limit="68.5"/>
                    <measurement group_id="O8" value="12" lower_limit="1.5" upper_limit="36.4"/>
                    <measurement group_id="O9" value="41" lower_limit="18.4" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 30, N= 21,22,15,19,10,20,18,16,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="32" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="26" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O5" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O6" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O7" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O8" value="94" lower_limit="69.8" upper_limit="99.84"/>
                    <measurement group_id="O9" value="44" lower_limit="19.8" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 365, N= 21,22,16,20,10,20,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="43" upper_limit="85.4"/>
                    <measurement group_id="O2" value="23" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="88" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O4" value="25" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O5" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O6" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O7" value="85" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O8" value="50" lower_limit="26" upper_limit="74"/>
                    <measurement group_id="O9" value="35" lower_limit="14.2" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1, N= 20,19,14,20,11,19,19,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O2" value="68" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O3" value="71" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O7" value="58" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O8" value="50" lower_limit="26" upper_limit="74"/>
                    <measurement group_id="O9" value="75" lower_limit="47.6" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 30, N= 17,20,10,20,7,14,19,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O2" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O3" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O4" value="55" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O5" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O8" value="88" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O9" value="69" lower_limit="41.3" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 365, N= 21,21,16,20,11,19,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="50" lower_limit="27.2" upper_limit="72.8"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="95" lower_limit="74" upper_limit="99.87"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="65" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 1, 20,22,12,20,11,20,17,18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="75.1" upper_limit="99.87"/>
                    <measurement group_id="O2" value="95" lower_limit="77.2" upper_limit="99.88"/>
                    <measurement group_id="O3" value="75" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O4" value="70" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O7" value="82" lower_limit="56.6" upper_limit="96.2"/>
                    <measurement group_id="O8" value="61" lower_limit="35.7" upper_limit="82.7"/>
                    <measurement group_id="O9" value="56" lower_limit="29.9" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 30, N= 18,22,15,19,11,18,17,16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O2" value="86" lower_limit="65.1" upper_limit="97.1"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="74" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O5" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O9" value="57" lower_limit="28.9" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (Day 365, N= 21,22,16,20,11,20,19,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="82" lower_limit="59.7" upper_limit="94.8"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O5" value="91" lower_limit="58.7" upper_limit="99.77"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O9" value="65" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1, N= 21,21,14,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O2" value="62" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O3" value="71" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="36" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O6" value="11" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O7" value="55" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O8" value="44" lower_limit="21.5" upper_limit="69.2"/>
                    <measurement group_id="O9" value="41" lower_limit="18.4" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 30, N= 21,21,15,20,11,18,20,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="57" lower_limit="34" upper_limit="78.2"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="82" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="83" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O7" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O9" value="38" lower_limit="15.2" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 365, N= 21,21,16,20,11,18,20,18,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.2" upper_limit="99.88"/>
                    <measurement group_id="O2" value="52" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O3" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O4" value="40" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O5" value="45" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="72" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O7" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O8" value="89" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O9" value="47" lower_limit="23" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>23. Number of Subjects With Solicited Local and Systemic Adverse Events Following Booster Vaccination in This Study.</title>
        <description>Number of subjects reporting solicited local and systemic adverse events after receiving a booster dose of MenABCWY vaccine or placebo. the below reported events are Erythema- Injection site erythema, Induration- Injection site induration, Pain-injection site pain, Arthralgia, Chills, Fatigue, Headache, Loss of Appetite, Myalgia, Nausea, Rash, Fever, Prevention- Prevention of Pain and/or Fever, Treatment- Treatment of Pain and/or Fever and Analgesic/Antipyr.: use of Analgesic/Antipyretics in pain and fever.</description>
        <time_frame>From day 1 (6 hours) through day 7 after any vaccination</time_frame>
        <population>Analysis was done on the Solicited Safety Set, i.e. all exposed subjects who provide post vaccination solicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
          </group>
          <group group_id="O7">
            <title>2B_Pbo</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of Placebo in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
          </group>
          <group group_id="O10">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O11">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>23. Number of Subjects With Solicited Local and Systemic Adverse Events Following Booster Vaccination in This Study.</title>
          <description>Number of subjects reporting solicited local and systemic adverse events after receiving a booster dose of MenABCWY vaccine or placebo. the below reported events are Erythema- Injection site erythema, Induration- Injection site induration, Pain-injection site pain, Arthralgia, Chills, Fatigue, Headache, Loss of Appetite, Myalgia, Nausea, Rash, Fever, Prevention- Prevention of Pain and/or Fever, Treatment- Treatment of Pain and/or Fever and Analgesic/Antipyr.: use of Analgesic/Antipyretics in pain and fever.</description>
          <population>Analysis was done on the Solicited Safety Set, i.e. all exposed subjects who provide post vaccination solicited adverse event data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="19"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs (N=26,24,17,23,11,21,6,21,19,19,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local (N=26,24,17,23,11,21,6,21,19,19,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (N=26,23,17,23,11,21,6,21,19,19,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (N=26,23,17,23,11,21,6,21,19,18,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=26,24,17,23,11,21,6,21,19,19,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic (N=26,24,17,23,11,21,6,21,19,19,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia(N=25,23,17,23,10,21,6,21,19,19,184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills(N=26,23,17,23,11,21,6,21,19,19,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue(N=26,23,17,23,11,21,6,21,19,19,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache(N=26,23,17,23,11,21,6,21,19,19,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss ofAppetite(N=26,23,17,23,11,21,6,21,19,19,186</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia(N=26,23,17,23,10,21,6,21,19,19,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea(N=26,23,17,23,11,21,6,21,19,19,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=26,23,17,23,11,21,6,21,18,19,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;38 °C (N=25,24,17,23,11,21,6,21,19,18,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention (N=25,23,17,23,11,21,6,21,19,19,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment (N=25,23,17,23,11,21,6,21,19,19,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyr. Pain (N=0,0,1,0,0,0,0,0,0,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyr. Fever (N=0,0,1,0,0,0,0,0,0,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24. Number of Subjects With Unsolicited (Any AEs and Possibly Related AEs) Following Booster Vaccination in This Study.</title>
        <description>Number of subjects reporting unsolicited AEs (any AEs and at least possibly related AEs) after receiving a booster dose of MenABCWY vaccine or placebo from Day 1 to Day 30.
Analysis was done on the Unsolicited Safety Set. All subjects in the exposed population who provided information about post-vaccination AEs or safety records at Day 30.</description>
        <time_frame>Day 1 through Day 30</time_frame>
        <population>Analysis was done on the Unsolicited Safety Set. All subjects in the exposed population who provided information about post-vaccination AEs or safety records at Day 30.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>2B_Pbo</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of Placebo in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O10">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>24. Number of Subjects With Unsolicited (Any AEs and Possibly Related AEs) Following Booster Vaccination in This Study.</title>
          <description>Number of subjects reporting unsolicited AEs (any AEs and at least possibly related AEs) after receiving a booster dose of MenABCWY vaccine or placebo from Day 1 to Day 30.
Analysis was done on the Unsolicited Safety Set. All subjects in the exposed population who provided information about post-vaccination AEs or safety records at Day 30.</description>
          <population>Analysis was done on the Unsolicited Safety Set. All subjects in the exposed population who provided information about post-vaccination AEs or safety records at Day 30.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="19"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>25. Number of Subjects With Unsolicited Adverse Events Following Booster Vaccination in This Study.</title>
        <description>Number of subjects reporting any serious unsolicited AEs (SAEs), possibly related SAEs, medically attended AEs, unsolicited AEs leading to withdrawal and deaths after receiving a booster dose of MenABCWY vaccine or placebo, are reported for the entire study period.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>Analysis was done on the Unsolicited Safety Set. All subjects in the exposed population who provided information about post-vaccination AEs or safety records at Day 30.</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>2B_Pbo</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of Placebo in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O10">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>25. Number of Subjects With Unsolicited Adverse Events Following Booster Vaccination in This Study.</title>
          <description>Number of subjects reporting any serious unsolicited AEs (SAEs), possibly related SAEs, medically attended AEs, unsolicited AEs leading to withdrawal and deaths after receiving a booster dose of MenABCWY vaccine or placebo, are reported for the entire study period.</description>
          <population>Analysis was done on the Unsolicited Safety Set. All subjects in the exposed population who provided information about post-vaccination AEs or safety records at Day 30.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="19"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least Possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>26. Number of Subjects With Unsolicited Adverse Leading to New Onset Chronic Disease (NOCD) Before Study Vaccination.</title>
        <description>Number of subjects reporting New Onset Chronic Disease (NOCD),from the end of the primary parental study V102_03 (NCT01272180) up to Day 1 visit in V102_03E1 study, is reported. (Any NOCD AEs: NOCD V102_03 (NCT01272180) vs. NOCD- Day 1, V102_03E1)</description>
        <time_frame>From primary parent study completion up to Day 1 in this study.</time_frame>
        <population>Analysis was done on the all enrolled set population. All screened subjects who have been enrolled (ie, attended the first clinic visit and received a subject ID).</population>
        <group_list>
          <group group_id="O1">
            <title>2OMV_OMV</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O2">
            <title>2OMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
          </group>
          <group group_id="O3">
            <title>2qOMV_qOMV</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
          </group>
          <group group_id="O4">
            <title>2qOMV_Pbo</title>
            <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study</description>
          </group>
          <group group_id="O5">
            <title>2B_OMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study</description>
          </group>
          <group group_id="O6">
            <title>2B_qOMV</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼OMV in this study</description>
          </group>
          <group group_id="O7">
            <title>2B_Pbo</title>
            <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of Placebo in this study.</description>
          </group>
          <group group_id="O8">
            <title>1M_OMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
          </group>
          <group group_id="O9">
            <title>1M_qOMV</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼OMV in this study.</description>
          </group>
          <group group_id="O10">
            <title>1M_Pbo</title>
            <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>26. Number of Subjects With Unsolicited Adverse Leading to New Onset Chronic Disease (NOCD) Before Study Vaccination.</title>
          <description>Number of subjects reporting New Onset Chronic Disease (NOCD),from the end of the primary parental study V102_03 (NCT01272180) up to Day 1 visit in V102_03E1 study, is reported. (Any NOCD AEs: NOCD V102_03 (NCT01272180) vs. NOCD- Day 1, V102_03E1)</description>
          <population>Analysis was done on the all enrolled set population. All screened subjects who have been enrolled (ie, attended the first clinic visit and received a subject ID).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="19"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events (AEs) between Day 1 (from 30 minutes) to Day 7; any unsolicited AE from Day 1 (from 30 minutes) to Day 30 and serious AE, medically attended AE, AE leading to withdrawal, death and NOCD from Day 1 to Day 365.</time_frame>
      <desc>Safety analysis was conducted on the solicited and unsolicited safety set cohorts that included only the exposed subjects who provided solicited adverse event data and post-vaccination AE data, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>2OMV_OMV</title>
          <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one booster dose of same vaccine in this study.</description>
        </group>
        <group group_id="E2">
          <title>2OMV_Pbo</title>
          <description>Subjects who previously received two doses of MenABCWY + OMV in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="E3">
          <title>2qOMV_qOMV</title>
          <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one booster dose of same vaccine in this study.</description>
        </group>
        <group group_id="E4">
          <title>2qOMV_Pbo</title>
          <description>Subjects who previously received two doses of MenABCWY + ¼ OMV in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="E5">
          <title>2B_OMV</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + OMV in this study.</description>
        </group>
        <group group_id="E6">
          <title>2B_qOMV</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
        </group>
        <group group_id="E7">
          <title>2B_Pbo</title>
          <description>Subjects who previously received two doses of rMenB + OMV in the parent study, received one dose of Placebo in this study.</description>
        </group>
        <group group_id="E8">
          <title>1M_OMV</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + OMV in this study.</description>
        </group>
        <group group_id="E9">
          <title>1M_qOMV</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of MenABCWY + ¼ OMV in this study.</description>
        </group>
        <group group_id="E10">
          <title>1M_Pbo</title>
          <description>Subjects who previously received one dose of MenACWY in the parent study, received one dose of saline solution in this study.</description>
        </group>
        <group group_id="E11">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="158" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="25" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="15" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="62" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="55" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="56" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="121" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Lice infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Post vaccination syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="28" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="31" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="56" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

